Retinoic	O
acid	O
activates	O
interferon	B-protein
regulatory	I-protein
factor-1	I-protein
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

All-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
the	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

ATRA	O
induces	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
of	O
APL	B-cell_line
cells	I-cell_line
into	O
mature	B-cell_type
granulocytes	I-cell_type
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
ATRA-dependent	O
growth	O
inhibition	O
and	O
cellular	O
differentiation	O
are	O
not	O
presently	O
understood	O
.	O

The	O
NB4	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
derived	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
APL	O
during	O
relapse	O
,	O
can	O
be	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
growth	O
and	O
differentiation	O
of	O
APL	B-cell_line
cells	I-cell_line
.	O

Because	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
regulatory	I-protein
factors	I-protein
(	O
IRF-1	B-protein
and	O
IRF-2	B-protein
)	O
and	O
other	O
IFN-inducible	B-protein
gene	I-protein
products	I-protein
regulate	O
cell	O
growth	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
these	O
genes	O
.	O

We	O
show	O
that	O
ATRA	O
directly	O
activates	O
IRF-1	B-DNA
gene	I-DNA
expression	O
,	O
followed	O
by	O
activation	O
of	O
IRF-2	B-protein
and	O
2'-5	B-protein
'	I-protein
oligoadenylate	I-protein
synthetase	I-protein
(	O
OAS	O
)	O
gene	O
expression	O
with	O
slower	O
kinetics	O
.	O

In	O
addition	O
to	O
NB4	O
cells	O
,	O
ATRA	O
also	O
activated	O
IRF-1	B-DNA
gene	I-DNA
expression	O
in	O
HL-60	B-cell_line
,	O
U937	B-cell_line
,	O
and	O
THP-1	B-cell_line
cells	I-cell_line
,	O
which	O
all	O
respond	O
to	O
ATRA	O
by	O
growth	O
inhibition	O
.	O

A	O
more	O
than	O
additive	O
increase	O
in	O
IRF-1	B-DNA
gene	I-DNA
expression	O
was	O
seen	O
with	O
ATRA	O
and	O
IFN-gamma	B-protein
in	O
NB4	B-cell_line
cells	I-cell_line
.	O

ATRA	O
did	O
not	O
activate	O
nuclear	O
factor	O
kappa	O
B	O
or	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
activation	O
pathways	O
,	O
suggesting	O
that	O
an	O
alternate	O
mechanism	O
is	O
involved	O
in	O
IRF-1	B-DNA
gene	I-DNA
activation	O
.	O

The	O
ATRA-induced	O
expression	O
of	O
IRF-1	B-protein
,	O
an	O
activator	O
of	O
transcription	O
and	O
repressor	O
of	O
transformation	O
,	O
may	O
be	O
one	O
of	O
the	O
molecular	O
mechanisms	O
of	O
ATRA-induced	O
growth	O
inhibition	O
,	O
and	O
the	O
basis	O
for	O
the	O
synergistic	O
actions	O
of	O
ATRA	O
and	O
IFNs	B-protein
in	O
myeloid	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Retinoic	NULL
Acid	NULL
Activates	NULL
Interferon	NULL
Regulatory	NULL
Factor-1	NULL
Gene	NULL
Expression	NULL
in	NULL
Myeloid	NULL
Cells	NULL
By	NULL
Sampsa	NULL
Matikainen	NULL
,	NULL
Tapani	NULL
Ronni	NULL
,	NULL
Mikko	NULL
Hurme	NULL
,	NULL
Richard	NULL
Pine	NULL
,	NULL
and	NULL
Ilkka	NULL
Julkunen	NULL
All-trans-retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
is	NULL
the	NULL
drug	NULL
of	NULL
choice	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
.	NULL

ATRA	NULL
induces	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
differentiation	NULL
of	NULL
APL	NULL
cells	NULL
into	NULL
mature	NULL
granulocytes	NULL
.	NULL

However	NULL
,	NULL
the	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
ATRA-dependent	NULL
growth	NULL
inhibition	NULL
and	NULL
cellular	NULL
differentiation	NULL
are	NULL
not	NULL
presently	NULL
understood	NULL
.	NULL

The	NULL
NB4	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
is	NULL
derived	NULL
from	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
APL	NULL
during	NULL
relapse	NULL
,	NULL
can	NULL
be	NULL
used	NULL
as	NULL
a	NULL
model	NULL
system	NULL
to	NULL
study	NULL
the	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
APL	NULL
cells	NULL
.	NULL

Because	NULL
interferon	NULL
(	NULL
IFN	NULL
)	NULL
regulatory	NULL
factors	NULL
(	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
)	NULL
and	NULL
other	NULL
IFN-inducible	NULL
gene	NULL
products	NULL
regulate	NULL
cell	NULL
growth	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effects	NULL
of	NULL
ATRA	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

We	NULL
show	NULL
that	NULL
ATRA	NULL
directly	NULL
activates	NULL
IRF-1	NULL
gene	NULL
expression	NULL
,	NULL
followed	NULL
by	NULL
activation	NULL
of	NULL
IRF-2	NULL
and	NULL
2'-5	NULL
'	NULL
oli-	NULL
LL-trans-retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
is	NULL
a	NULL
potential	NULL
regulator	NULL
of	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
.	NULL

ATRA	NULL
is	NULL
a	NULL
natural	NULL
and	NULL
biologically	NULL
active	NULL
metabolite	NULL
of	NULL
vitamin	NULL
A	NULL
.	NULL

It	NULL
modifies	NULL
gene	NULL
expression	NULL
by	NULL
binding	NULL
to	NULL
its	NULL
specific	NULL
nuclear	NULL
receptor	NULL
.	NULL

Several	NULL
members	NULL
within	NULL
two	NULL
families	NULL
of	NULL
retinoid	NULL
receptors	NULL
,	NULL
RAR	NULL
and	NULL
RXR	NULL
,	NULL
have	NULL
been	NULL
cloned	NULL
,	NULL
and	NULL
their	NULL
structures	NULL
have	NULL
been	NULL
described	NULL
in	NULL
detail	NULL
in	NULL
a	NULL
recent	NULL
review	NULL
.	NULL
``	NULL

These	NULL
receptors	NULL
belong	NULL
to	NULL
the	NULL
superfamily	NULL
of	NULL
nuclear	NULL
receptors	NULL
,	NULL
among	NULL
which	NULL
are	NULL
also	NULL
steroid	NULL
,	NULL
mineralocorticoid	NULL
,	NULL
thyroid	NULL
,	NULL
and	NULL
vitamin	NULL
D	NULL
receptors	NULL
.	NULL

They	NULL
are	NULL
ligand-activated	NULL
transcription	NULL
factors	NULL
and	NULL
affect	NULL
gene	NULL
expression	NULL
directly	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
.	NULL
'	NULL

Acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
is	NULL
a	NULL
form	NULL
of	NULL
cancer	NULL
associated	NULL
with	NULL
a	NULL
15	NULL
;	NULL
17	NULL
translocation	NULL
,	NULL
where	NULL
the	NULL
RAR-a	NULL
is	NULL
translocated	NULL
from	NULL
chromosome	NULL
17	NULL
to	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
pml	NULL
)	NULL
locus	NULL
on	NULL
chromosome	NULL
15	NULL
.	NULL

This	NULL
results	NULL
in	NULL
the	NULL
synthesis	NULL
of	NULL
a	NULL
fusion	NULL
transcript	NULL
giving	NULL
rise	NULL
to	NULL
a	NULL
respective	NULL
PML/RAR-a	NULL
fusion	NULL
protein	NULL
.	NULL
'	NULL

''	NULL
*	NULL
PML/RAR-a	NULL
fusion	NULL
protein	NULL
can	NULL
function	NULL
as	NULL
a	NULL
receptor	NULL
for	NULL
retinoids	NULL
and	NULL
apparently	NULL
contributes	NULL
to	NULL
the	NULL
leukemogenesis	NULL
by	NULL
inhibiting	NULL
the	NULL
differentiation	NULL
of	NULL
promyelocytes	NULL
.	NULL

It	NULL
may	NULL
also	NULL
promote	NULL
cell	NULL
survival	NULL
by	NULL
inhibiting	NULL
apoptosis	NULL
,	NULL
the	NULL
programed	NULL
cell	NULL
death	NULL
.	NULL
``	NULL

''	NULL
The	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
ATRA-dependent	NULL
differentiation	NULL
are	NULL
presently	NULL
not	NULL
understood	NULL
.	NULL

However	NULL
,	NULL
APL	NULL
cells	NULL
are	NULL
responsive	NULL
to	NULL
ATRA	NULL
,	NULL
which	NULL
is	NULL
able	NULL
to	NULL
induce	NULL
differentiation	NULL
From	NULL
the	NULL
Molecular	NULL
Biology	NULL
Programme	NULL
,	NULL
National	NULL
Public	NULL
Health	NULL
Institute	NULL
,	NULL
Helsinki	NULL
;	NULL
the	NULL
Department	NULL
of	NULL
Biomedical	NULL
Sciences	NULL
,	NULL
University	NULL
of	NULL
Tampere	NULL
,	NULL
Tampere	NULL
,	NULL
Finland	NULL
;	NULL
and	NULL
the	NULL
Public	NULL
Health	NULL
Research	NULL
Institute	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
.	NULL

Submitted	NULL
July	NULL
18	NULL
,	NULL
1995	NULL
;	NULL
accepted	NULL
March	NULL
4	NULL
,	NULL
1996	NULL
.	NULL

Supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Academy	NULL
of	NULL
Finland	NULL
,	NULL
Finnish	NULL
Cancer	NULL
Organization	NULL
,	NULL
Finnish	NULL
Cultural	NULL
Foundation	NULL
,	NULL
and	NULL
Paulo	NULL
Foundation	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Sampsa	NULL
Matikainen	NULL
,	NULL
PhD	NULL
,	NULL
National	NULL
Public	NULL
Health	NULL
Institute	NULL
,	NULL
Mannerheimintie	NULL
166	NULL
,	NULL
FIN-00300	NULL
Helsinki	NULL
,	NULL
Finland	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

Â©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/96/8801	NULL
114	NULL
goadenylate	NULL
synthetase	NULL
(	NULL
OAS	NULL
)	NULL
gene	NULL
expression	NULL
with	NULL
slower	NULL
kinetics	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
NB4	NULL
cells	NULL
,	NULL
ATRA	NULL
also	NULL
activated	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
HL-60	NULL
,	NULL
U937	NULL
,	NULL
and	NULL
THP-1	NULL
ceils	NULL
,	NULL
which	NULL
all	NULL
respond	NULL
to	NULL
ATRA	NULL
by	NULL
growth	NULL
inhibition	NULL
.	NULL

A	NULL
more	NULL
than	NULL
additive	NULL
increase	NULL
in	NULL
IRF-1	NULL
gene	NULL
expression	NULL
was	NULL
seen	NULL
with	NULL
ATRA	NULL
and	NULL
IFN-y	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

ATRA	NULL
did	NULL
not	NULL
activate	NULL
nuclear	NULL
factor	NULL
xB	NULL
or	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
activation	NULL
pathways	NULL
,	NULL
suggesting	NULL
that	NULL
an	NULL
alternate	NULL
mechanism	NULL
is	NULL
involved	NULL
in	NULL
IRF-1	NULL
gene	NULL
activation	NULL
.	NULL

The	NULL
ATRA-induced	NULL
expression	NULL
of	NULL
IRF-1	NULL
,	NULL
an	NULL
activator	NULL
of	NULL
transcription	NULL
and	NULL
repres-sor	NULL
of	NULL
transformation	NULL
,	NULL
may	NULL
be	NULL
one	NULL
of	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
ATRA-induced	NULL
growth	NULL
inhibition	NULL
,	NULL
and	NULL
the	NULL
basis	NULL
for	NULL
the	NULL
synergistic	NULL
actions	NULL
of	NULL
ATRA	NULL
and	NULL
IFNs	NULL
in	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
.	NULL

Â©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

of	NULL
APL	NULL
cells	NULL
into	NULL
mature	NULL
granulocytes	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
ATRA	NULL
has	NULL
successfully	NULL
been	NULL
used	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
APL	NULL
.	NULL

``	NULL
Â°	NULL
The	NULL
NB4	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
is	NULL
derived	NULL
from	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
an	NULL
APL	NULL
during	NULL
relapse	NULL
.	NULL

This	NULL
cell	NULL
line	NULL
carries	NULL
the	NULL
15	NULL
;	NULL
17	NULL
translocation	NULL
and	NULL
expresses	NULL
the	NULL
PML/RAR-a	NULL
fusion	NULL
protein	NULL
.	NULL
'	NULL

In	NULL
addition	NULL
to	NULL
NB4	NULL
cells	NULL
,	NULL
HL-60	NULL
,	NULL
THP-1	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
have	NULL
been	NULL
established	NULL
as	NULL
useful	NULL
model	NULL
systems	NULL
to	NULL
study	NULL
the	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
.	NULL

Interferons	NULL
(	NULL
IFNs	NULL
)	NULL
belong	NULL
to	NULL
the	NULL
family	NULL
of	NULL
cytokines	NULL
.	NULL

They	NULL
have	NULL
antiviral	NULL
,	NULL
antiproliferative	NULL
,	NULL
and	NULL
immunomodulatory	NULL
functions	NULL
.	NULL
``	NULL

''	NULL
Recent	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
IFNs	NULL
and	NULL
ATRA	NULL
have	NULL
synergistic	NULL
antiproliferative	NULL
and	NULL
differentiating	NULL
actions	NULL
.	NULL
``	NULL

''	NULL
IFNs	NULL
have	NULL
attained	NULL
wide	NULL
use	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
several	NULL
diseases	NULL
,	NULL
such	NULL
as	NULL
viral	NULL
hepatitis	NULL
and	NULL
various	NULL
forms	NULL
of	NULL
cancer	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
responsible	NULL
for	NULL
the	NULL
antiproliferative	NULL
actions	NULL
of	NULL
IFNs	NULL
are	NULL
still	NULL
relatively	NULL
poorly	NULL
known	NULL
,	NULL
even	NULL
though	NULL
several	NULL
IFN-inducible	NULL
genes	NULL
like	NULL
2'-5	NULL
'	NULL
oligoadenylate	NULL
synthetase	NULL
(	NULL
OAS	NULL
)	NULL
,	NULL
2'-5	NULL
'	NULL
oligoadenylate-activated	NULL
RNAase	NULL
L	NULL
,	NULL
dsRNA-activated	NULL
protein	NULL
kinase	NULL
(	NULL
PKR	NULL
)	NULL
,	NULL
and	NULL
IFN	NULL
regulatory	NULL
factors-1	NULL
and	NULL
-2	NULL
(	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
)	NULL
have	NULL
been	NULL
tightly	NULL
linked	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
prolifera-tion	NULL
.	NULL
'	NULL

''	NULL
``	NULL
*	NULL
``	NULL
``	NULL
Of	NULL
special	NULL
interest	NULL
is	NULL
that	NULL
IRF	NULL
proteins	NULL
appear	NULL
to	NULL
be	NULL
capable	NULL
of	NULL
regulating	NULL
IFN	NULL
and	NULL
IFN-inducible	NULL
gene	NULL
expression	NULL
and	NULL
cellular	NULL
proliferation	NULL
.	NULL

IRF-1	NULL
functions	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
,	NULL
whereas	NULL
IRF-2	NULL
functions	NULL
as	NULL
a	NULL
transcriptional	NULL
repressor	NULL
.	NULL
``	NULL

In	NULL
their	NULL
N-terminal	NULL
DNA-binding	NULL
do-main	NULL
,	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
share	NULL
considerable	NULL
homology	NULL
with	NULL
the	NULL
p48	NULL
protein	NULL
of	NULL
the	NULL
interferon-a	NULL
stimulated	NULL
gene	NULL
factor	NULL
3	NULL
(	NULL
ISGF3	NULL
)	NULL
complex	NULL
and	NULL
the	NULL
c-myb	NULL
protein	NULL
.	NULL

'*	NULL
IRFs	NULL
and	NULL
p48	NULL
can	NULL
also	NULL
bind	NULL
to	NULL
partially	NULL
similar	NULL
DNA	NULL
elements	NULL
in	NULL
the	NULL
regulatory	NULL
regions	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
.	NULL
``	NULL

The	NULL
IRF-1	NULL
gene	NULL
is	NULL
also	NULL
constantly	NULL
deleted	NULL
in	NULL
leukemia	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
genomic	NULL
region	NULL
5q-associated	NULL
leukemias	NULL
or	NULL
preleukemic	NULL
myelodys-plastic	NULL
syndromes	NULL
.	NULL
``	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
loss	NULL
of	NULL
the	NULL
functional	NULL
IRF-1	NULL
system	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
development	NULL
of	NULL
certain	NULL
leukemias	NULL
.	NULL

To	NULL
understand	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
ATRA-induced	NULL
growth	NULL
inhibition	NULL
and	NULL
cellular	NULL
differentiation	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
ATRA	NULL
on	NULL
IRF	NULL
and	NULL
other	NULL
IFN-inducible	NULL
gene	NULL
expression	NULL
in	NULL
promyelocytic	NULL
NB4	NULL
cells	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
ATRA	NULL
can	NULL
rapidly	NULL
upregulate	NULL
IRF-1	NULL
gene	NULL
expres-	NULL
Blood	NULL
,	NULL
Vol	NULL
88	NULL
,	NULL
No	NULL
1	NULL
(	NULL
July	NULL
1	NULL
)	NULL
,	NULL
1996	NULL
:	NULL
pp	NULL
114-123	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

RETINOIC	NULL
ACID	NULL
ACTIVATES	NULL
IRF-1	NULL
GENE	NULL
EXPRESSION	NULL
sion	NULL
,	NULL
which	NULL
apparently	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
other	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

-	NULL
The	NULL
HL-60	NULL
,	NULL
THP-1	NULL
,	NULL
and	NULL
U937	NULL
cell	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
[	NULL
ATCC	NULL
]	NULL
Rock-ville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
NB4	NULL
cell	NULL
line	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
M.	NULL
Lanotte	NULL
(	NULL
INSERM	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Flow	NULL
Laboratories	NULL
,	NULL
Irvine	NULL
,	NULL
Scotland	NULL
)	NULL
containing	NULL
10	NULL
mmol/	NULL
L	NULL
HEPES	NULL
,	NULL
2	NULL
mmol/L	NULL
L-glutamine	NULL
,	NULL
antibiotics	NULL
,	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
GIBCO	NULL
Life	NULL
Technologies	NULL
Ltd	NULL
,	NULL
Paisley	NULL
,	NULL
Scotland	NULL
)	NULL
;	NULL
70	NULL
umol/	NULL
L	NULL
A-mercaptoethanol	NULL
was	NULL
added	NULL
to	NULL
THP-1	NULL
cells	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
ATCC	NULL
.	NULL

For	NULL
human	NULL
macrophages	NULL
,	NULL
leukocyte-rich	NULL
buffy-coat	NULL
fractions	NULL
were	NULL
obtained	NULL
from	NULL
healthy	NULL
blood	NULL
donors	NULL
from	NULL
the	NULL
Finnish	NULL
Red	NULL
Cross	NULL
Blood	NULL
Transfusion	NULL
Center	NULL
(	NULL
Helsinki	NULL
,	NULL
Finland	NULL
)	NULL
,	NULL
and	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
by	NULL
centrifugation	NULL
on	NULL
a	NULL
Ficoll	NULL
Hypaque	NULL
gradient	NULL
(	NULL
Phar-macia	NULL
Biotech	NULL
Inc	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
fetal	NULL
calf	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
penicillin	NULL
(	NULL
0.6	NULL
pg/mL	NULL
)	NULL
,	NULL
streptomycin	NULL
(	NULL
60	NULL
ug/mL	NULL
)	NULL
,	NULL
gluta-mine	NULL
(	NULL
2	NULL
mmol/L	NULL
)	NULL
,	NULL
and	NULL
HEPES	NULL
(	NULL
20	NULL
mmol/L	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
adhered	NULL
onto	NULL
six-well	NULL
plates	NULL
(	NULL
Falcon	NULL
,	NULL
Lincoln	NULL
Park	NULL
,	NULL
NJ	NULL
)	NULL
for	NULL
1	NULL
hour	NULL
and	NULL
then	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
cold	NULL
phosphate-buffered	NULL
saline	NULL
.	NULL

Adherent	NULL
cells	NULL
were	NULL
grown	NULL
for	NULL
1	NULL
week	NULL
in	NULL
Macrophage-SFM	NULL
medium	NULL
(	NULL
GIBCO	NULL
Life	NULL
Technologies	NULL
Ltd	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
.	NULL

Thereafter	NULL
,	NULL
more	NULL
than	NULL
90	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
monocytes/macrophages	NULL
according	NULL
to	NULL
morphology	NULL
and	NULL
CD14	NULL
expression	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Reagents	NULL
.	NULL

ATRA	NULL
was	NULL
purchased	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co	NULL
(	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Human	NULL
leukocyte	NULL
IFN-a	NULL
6	NULL
x	NULL
10Â°	NULL
IU/mL	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Kari	NULL
Cantell	NULL
from	NULL
our	NULL
Institute	NULL
.	NULL

Human	NULL
IFN-y	NULL
1	NULL
x	NULL
10Â°TU/mL	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
Finnish	NULL
Red	NULL
Cross	NULL
Blood	NULL
Transfusion	NULL
Center	NULL
and	NULL
prepared	NULL
and	NULL
purified	NULL
as	NULL
described	NULL
elsewhere	NULL
.	NULL
``	NULL

Re-combinant	NULL
human	NULL
tumor	NULL
necrosis	NULL
factor-e	NULL
(	NULL
TNF-a	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
(	NULL
Abingdon	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

RNA	NULL
isolation	NULL
and	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

-	NULL
All	NULL
experiments	NULL
were	NULL
performed	NULL
during	NULL
the	NULL
exponential	NULL
growth	NULL
phase	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
stimuli	NULL
and	NULL
harvested	NULL
at	NULL
the	NULL
times	NULL
indi-cated	NULL
,	NULL
and	NULL
total	NULL
cellular	NULL
RNA	NULL
or	NULL
polyadenylated	NULL
(	NULL
polyA	NULL
)	NULL
*	NULL
RNA	NULL
was	NULL
isolated	NULL
.	NULL

Total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
by	NULL
guanidium	NULL
isothiocya-nate	NULL
lysis	NULL
of	NULL
the	NULL
cells	NULL
,	NULL
followed	NULL
by	NULL
centrifugation	NULL
through	NULL
a	NULL
CsCl	NULL
cushion	NULL
.	NULL
``	NULL

The	NULL
(	NULL
polyA	NULL
)	NULL
*	NULL
RNA	NULL
was	NULL
bound	NULL
to	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-cellulose	NULL
(	NULL
Boehringer	NULL
,	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
directly	NULL
from	NULL
cell	NULL
lysates	NULL
and	NULL
eluted	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

Both	NULL
total	NULL
cellular	NULL
RNA	NULL
and	NULL
(	NULL
polyA	NULL
)	NULL
*	NULL
RNA	NULL
were	NULL
quantified	NULL
pho-tometrically	NULL
,	NULL
and	NULL
samples	NULL
containing	NULL
equal	NULL
amounts	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
(	NULL
30	NULL
ug	NULL
)	NULL
or	NULL
(	NULL
polyA	NULL
)	NULL
*	NULL
RNA	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
were	NULL
size-fractionated	NULL
on	NULL
1.0	NULL
%	NULL
formaldehyde-agarose	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
a	NULL
Hybond-N	NULL
nylon	NULL
membrane	NULL
(	NULL
Amersham	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
UK	NULL
)	NULL
,	NULL
and	NULL
hybridized	NULL
with	NULL
human	NULL
IRF-1	NULL
,	NULL
IRF-2	NULL
,	NULL
``	NULL
Â°	NULL
and	NULL
OAS*	NULL
cDNA	NULL
probes	NULL
.	NULL

RNA	NULL
levels	NULL
in	NULL
the	NULL
nylon	NULL
membranes	NULL
were	NULL
also	NULL
quantified	NULL
using	NULL
the	NULL
glyceraldehyde	NULL
phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
cDNA	NULL
probe	NULL
.	NULL

The	NULL
probes	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
Â«	NULL
-*Â°P	NULL
]	NULL
dCTP	NULL
(	NULL
3,000	NULL
Ci/mmol	NULL
;	NULL
Amersham	NULL
)	NULL
by	NULL
a	NULL
random-primed	NULL
DNA-labeling	NULL
kit	NULL
purchased	NULL
from	NULL
Boehringer	NULL
.	NULL

Prehybridiza-tions	NULL
and	NULL
hybridizations	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
5	NULL
%	NULL
Denhardt	NULL
solution	NULL
,	NULL
5	NULL
%	NULL
SSPE	NULL
,	NULL
and	NULL
0.5	NULL
%	NULL
sodium	NULL
dodecy	NULL
!	NULL

sulfate	NULL
(	NULL
SDS	NULL
)	NULL
.	NULL

Filters	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
1	NULL
%	NULL
SSC	NULL
(	NULL
1	NULL
%	NULL
SSC	NULL
is	NULL
0.15	NULL
mol/L	NULL
NaCl	NULL
plus	NULL
0.015	NULL
mol/L	NULL
sodium	NULL
citrate	NULL
)	NULL
plus	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
minutes	NULL
and	NULL
once	NULL
at	NULL
60Â°C	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

The	NULL
filters	NULL
were	NULL
then	NULL
exposed	NULL
to	NULL
Kodak	NULL
AR	NULL
X-Omat	NULL
films	NULL
(	NULL
Eastman	NULL
Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
at	NULL
-70Â°C	NULL
with	NULL
intensifying	NULL
screens	NULL
.	NULL

Anti-IRF-1	NULL
antibody	NULL
.	NULL

-	NULL
Subcloning	NULL
of	NULL
the	NULL
human	NULL
IRF-1	NULL
cDNA	NULL
coding	NULL
region	NULL
``	NULL
``	NULL
into	NULL
the	NULL
pGEM3zf	NULL
(	NULL
+	NULL
)	NULL
vector	NULL
has	NULL
been	NULL
described	NULL
115	NULL
previously	NULL
.	NULL
``	NULL

After	NULL
sequence	NULL
analysis	NULL
,	NULL
the	NULL
IRF-1	NULL
insert	NULL
was	NULL
isolated	NULL
with	NULL
BamHI	NULL
and	NULL
further	NULL
subcloned	NULL
into	NULL
a	NULL
Bg/lI	NULL
site	NULL
of	NULL
the	NULL
pGEX2T*	NULL
'	NULL
vector	NULL
.	NULL

The	NULL
pGEX2T	NULL
*	NULL
'	NULL
vector	NULL
is	NULL
modified	NULL
from	NULL
the	NULL
pGEX2T	NULL
expression	NULL
vector	NULL
(	NULL
Pharmacia	NULL
)	NULL
by	NULL
inserting	NULL
a	NULL
linker	NULL
sequence	NULL
,	NULL
GATCCA-AGATCTTG	NULL
,	NULL
in	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
the	NULL
original	NULL
pGEX2T	NULL
vector	NULL
(	NULL
Bglll	NULL
site	NULL
underlined	NULL
)	NULL
to	NULL
change	NULL
the	NULL
open	NULL
reading	NULL
frame	NULL
to	NULL
+1	NULL
.	NULL

IRF-1	NULL
was	NULL
expressed	NULL
in	NULL
E	NULL
coli	NULL
strain	NULL
BL21	NULL
(	NULL
DE3	NULL
)	NULL
as	NULL
a	NULL
glutathione	NULL
S-transferase	NULL
(	NULL
GST	NULL
)	NULL
fusion	NULL
protein	NULL
,	NULL
and	NULL
was	NULL
purified	NULL
in	NULL
an	NULL
8	NULL
%	NULL
prepara-tive	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
(	NULL
Prep-Cell	NULL
;	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Denatured	NULL
GST-IRF-1	NULL
fusion	NULL
protein	NULL
was	NULL
used	NULL
to	NULL
immunize	NULL
guinea	NULL
pigs	NULL
.	NULL

Pooled	NULL
antisera	NULL
from	NULL
two	NULL
guinea	NULL
pigs	NULL
was	NULL
used	NULL
in	NULL
the	NULL
experiments	NULL
.	NULL

It	NULL
recognized	NULL
in	NULL
vitro-translated	NULL
IRF-1	NULL
protein	NULL
in	NULL
Western	NULL
blots	NULL
and	NULL
in	NULL
immunoprecipita-tion	NULL
.	NULL

Nuclear	NULL
run-off	NULL
analysis	NULL
.	NULL

-	NULL
Isolation	NULL
of	NULL
nuclei	NULL
from	NULL
cells	NULL
and	NULL
nuclear	NULL
run-off	NULL
analysis	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
method	NULL
of	NULL
Greenberg	NULL
and	NULL
Ziff	NULL
.	NULL
``	NULL

This	NULL
method	NULL
has	NULL
been	NULL
described	NULL
in	NULL
detail	NULL
elsewhere	NULL
.	NULL
``	NULL

Electrophoretic	NULL
mobility-shift	NULL
assay	NULL
.	NULL

-	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

'	NULL
Nuclear	NULL
protein/DNA-binding	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
20	NULL
gL	NULL
containing	NULL
5	NULL
ug	NULL
nuclear-extract	NULL
protein	NULL
,	NULL
10	NULL
mmol/L	NULL
HEPES-KOH	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
100	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
1	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
1	NULL
mmol/L	NULL
dithiothreitol	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
2	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
as	NULL
a	NULL
nonspecific	NULL
competitor	NULL
.	NULL

The	NULL
22-bp	NULL
nuclear	NULL
factor	NULL
Â«	NULL
B	NULL
(	NULL
NF-	NULL
Â«	NULL
B	NULL
)	NULL
-binding	NULL
oligonucleotide	NULL
(	NULL
5-AGTTGAGGG-GACTITCCCAGCC-3	NULL
'	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Promega	NULL
(	NULL
Madison	NULL
,	NULL
WID	NULL
)	NULL
.	NULL

y-Interferon	NULL
activation	NULL
stie	NULL
(	NULL
GAS	NULL
)	NULL
(	NULL
5-AGCTTCAGCCTG-ATTTCCCCGAAATGACGGA-3	NULL
'	NULL
)	NULL
,	NULL
high-affinity	NULL
C-sis-inducible	NULL
element	NULL
(	NULL
SIE	NULL
)	NULL
(	NULL
5-GATCTAGGGATTITTCCGGGAAATGAAGCT-3	NULL
'	NULL
)	NULL
,	NULL
and	NULL
interferon-	NULL
stimulated	NULL
response	NULL
element	NULL
15	NULL
(	NULL
ISRE15	NULL
)	NULL
(	NULL
5'-AGCTTGATCGGGAAAGGGAAACCGAAACTGAAGCCA	NULL
)	NULL
oli-gonucleotides	NULL
were	NULL
synthesized	NULL
locally	NULL
by	NULL
an	NULL
Applied	NULL
Biosystems	NULL
(	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
oligonucleotide	NULL
synthesizer	NULL
and	NULL
purified	NULL
on	NULL
PAGE	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
8	NULL
mol/L	NULL
urea	NULL
.	NULL

The	NULL
probes	NULL
were	NULL
labeled	NULL
by	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

The	NULL
binding	NULL
reaction	NULL
was	NULL
performed	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
on	NULL
4	NULL
%	NULL
nondenaturing	NULL
low-ionic-strength	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
0.25	NULL
x	NULL
TBE	NULL
(	NULL
Tris-borate/EDTA	NULL
)	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

Gel	NULL
electrophoresis	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

-	NULL
SDS-PAGE	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
Laemmli	NULL
buffer	NULL
systems	NULL
.	NULL
``	NULL

Proteins	NULL
separated	NULL
on	NULL
gels	NULL
were	NULL
transferred	NULL
onto	NULL
Immobilon-P	NULL
(	NULL
polyvinylidene	NULL
difluoride	NULL
)	NULL
membranes	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
with	NULL
an	NULL
Isophor	NULL
electrotransfer	NULL
apparatus	NULL
(	NULL
Hoeffer	NULL
Scientific	NULL
Instruments	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
at	NULL
200	NULL
raA	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

Primary	NULL
anti-IRF-1	NULL
guinea	NULL
pig	NULL
antibodies	NULL
(	NULL
dilution	NULL
1:1,000	NULL
)	NULL
were	NULL
bound	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
containing	NULL
5	NULL
%	NULL
nonfat	NULL
milk	NULL
for	NULL
2	NULL
hours	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
followed	NULL
by	NULL
secondary-antibody	NULL
(	NULL
1:2,000	NULL
dilution	NULL
)	NULL
binding	NULL
with	NULL
peroxidase	NULL
rabbit	NULL
anti-guinea	NULL
pig	NULL
antibodies	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
bands	NULL
were	NULL
visualized	NULL
by	NULL
an	NULL
ECL	NULL
chemilumi-nescence	NULL
system	NULL
,	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Concentrations	NULL
of	NULL
protein	NULL
samples	NULL
were	NULL
measured	NULL
with	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
kit	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
IRF-1	NULL
,	NULL
IRF-2	NULL
,	NULL
and	NULL
OAS	NULL
genes	NULL
in	NULL
promyelocytic	NULL
NB4	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL

IRF-1	NULL
,	NULL
a	NULL
transcriptional	NULL
activator	NULL
,	NULL
and	NULL
IRF-2	NULL
,	NULL
a	NULL
transcriptional	NULL
repressor	NULL
,	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IFN-	NULL
$	NULL
and	NULL
IFN-inducible	NULL
gene	NULL
expression	NULL
and	NULL
cellular	NULL
transformation	NULL
.	NULL
``	NULL

Since	NULL
ATRA	NULL
is	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
cellular	NULL
differentiation	NULL
of	NULL
promyelocytic	NULL
cells	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
determine	NULL
whether	NULL
it	NULL
has	NULL
an	NULL
effect	NULL
on	NULL
IRF-1	NULL
,	NULL
IRF-2	NULL
,	NULL
or	NULL
IFN-inducible	NULL
OAS	NULL
gene	NULL
expression	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
treated	NULL
promyelocytic	NULL
NB4	NULL
cells	NULL
with	NULL
1	NULL
Lmol/	NULL
L	NULL
ATRA	NULL
,	NULL
collected	NULL
cells	NULL
at	NULL
different	NULL
time	NULL
points	NULL
after	NULL
induc-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

116	NULL
tion	NULL
,	NULL
and	NULL
analyzed	NULL
steady-state	NULL
IRF-1	NULL
,	NULL
IRF-2	NULL
,	NULL
and	NULL
OAS	NULL
mRNA	NULL
levels	NULL
by	NULL
Northern	NULL
blotting	NULL
.	NULL

IRF-1	NULL
mRNA	NULL
levels	NULL
were	NULL
clearly	NULL
elevated	NULL
already	NULL
1	NULL
hour	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
steadily	NULL
increasing	NULL
thereafter	NULL
and	NULL
staying	NULL
at	NULL
constant	NULL
elevated	NULL
levels	NULL
up	NULL
to	NULL
72	NULL
hours	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

The	NULL
data	NULL
suggest	NULL
that	NULL
IRF-1	NULL
gene	NULL
expression	NULL
is	NULL
directly	NULL
induced	NULL
by	NULL
ATRA	NULL
.	NULL

IRF-2	NULL
mRNA	NULL
None	NULL
RA	NULL
th	NULL
RA	NULL
3h	NULL
RA	NULL
6h	NULL
RA	NULL
12h	NULL
RA	NULL
24h	NULL
RA	NULL
48h	NULL
RA	NULL
72h	NULL
IRF-1	NULL
IRF-2	NULL
OAS	NULL
GAPDH	NULL
12	NULL
10	NULL
8	NULL
s	NULL
S	NULL
8	NULL
4	NULL
<	NULL
E2	NULL
E	NULL
2	NULL
S	NULL
%	NULL
qs	NULL
|	NULL
Â©	NULL
10	NULL
|	NULL
2	NULL
a	NULL
-	NULL
8	NULL
|	NULL
0	NULL
3	NULL
6	NULL
|	NULL
G	NULL
8	NULL
G|	NULL
2	NULL
o	NULL
0	NULL
1	NULL
3	NULL
6	NULL
12	NULL
-	NULL
24	NULL
-	NULL
48	NULL
_	NULL
72	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Fig	NULL
1	NULL
.	NULL

Expression	NULL
of	NULL
IRF-1	NULL
,	NULL
IRF-2	NULL
,	NULL
and	NULL
OAS	NULL
genes	NULL
in	NULL
NB4	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
mol/L	NULL
ATRA	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
collected	NULL
at	NULL
the	NULL
times	NULL
indicated	NULL
and	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
was	NULL
isolated	NULL
.	NULL

Samples	NULL
(	NULL
5	NULL
ug	NULL
mRNA	NULL
)	NULL
were	NULL
fractionated	NULL
on	NULL
agarose	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
,	NULL
and	NULL
then	NULL
hybridized	NULL
to	NULL
the	NULL
IRF-1	NULL
,	NULL
IRF-2	NULL
,	NULL
and	NULL
OAS	NULL
cDNA	NULL
probes	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
also	NULL
hybridized	NULL
to	NULL
a	NULL
constant	NULL
probe	NULL
(	NULL
GAPDH	NULL
)	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
RNA	NULL
loading	NULL
in	NULL
each	NULL
lane	NULL
was	NULL
equal	NULL
.	NULL

MATIKAINEN	NULL
ET	NULL
AL	NULL
Time	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
hours	NULL
)	NULL
0	NULL
1	NULL
3	NULL
6	NULL
12	NULL
24	NULL
Suan	NULL
sae	NULL
wae	NULL
Wa	NULL
aut	NULL
aet	NULL
<	NULL
--	NULL
GAPDH	NULL
mRNA	NULL
Fig	NULL
2	NULL
.	NULL

-	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
are	NULL
upregulated	NULL
by	NULL
ATRA	NULL
in	NULL
myeloblastic	NULL
HL-60	NULL
cells	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
mol/L	NULL
ATRA	NULL
and	NULL
then	NULL
collected	NULL
,	NULL
and	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
.	NULL

Samples	NULL
(	NULL
30	NULL
ug	NULL
total	NULL
RNA	NULL
)	NULL
were	NULL
fractionated	NULL
on	NULL
agarose	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
,	NULL
and	NULL
then	NULL
hybridized	NULL
to	NULL
the	NULL
IRF-1	NULL
cDNA	NULL
probe	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
also	NULL
hybridized	NULL
to	NULL
a	NULL
constant	NULL
probe	NULL
(	NULL
GAPDH	NULL
)	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
RNA	NULL
loading	NULL
in	NULL
each	NULL
lane	NULL
was	NULL
equal	NULL
.	NULL

showed	NULL
higher	NULL
basal	NULL
levels	NULL
in	NULL
NB4	NULL
cells	NULL
as	NULL
compared	NULL
with	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
.	NULL

ATRA	NULL
apparently	NULL
had	NULL
no	NULL
direct	NULL
effect	NULL
on	NULL
IRF-2	NULL
steady-state	NULL
mRNA	NULL
levels	NULL
at	NULL
early	NULL
time	NULL
points	NULL
after	NULL
ATRA	NULL
induction	NULL
.	NULL

However	NULL
,	NULL
IRF-2	NULL
mRNA	NULL
levels	NULL
increased	NULL
6	NULL
hours	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
but	NULL
the	NULL
induction	NULL
remained	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
as	NULL
compared	NULL
with	NULL
that	NULL
seen	NULL
for	NULL
the	NULL
IRF-1	NULL
gene	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

Basal	NULL
OAS	NULL
mRNA	NULL
expression	NULL
was	NULL
at	NULL
an	NULL
undetectable	NULL
level	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

A	NULL
clear	NULL
increase	NULL
in	NULL
steady-state	NULL
OAS	NULL
mRNA	NULL
levels	NULL
was	NULL
found	NULL
starting	NULL
at	NULL
24	NULL
hours	NULL
,	NULL
markedly	NULL
increasing	NULL
thereafter	NULL
up	NULL
to	NULL
72	NULL
hours	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

IRF-1	NULL
mRNA	NULL
levels	NULL
are	NULL
rapidly	NULL
upregulated	NULL
by	NULL
ATRA	NULL
in	NULL
myeloblastic	NULL
HL-60	NULL
cells	NULL
.	NULL

HL-60	NULL
cells	NULL
are	NULL
myeloblastic	NULL
leukemia	NULL
cells	NULL
that	NULL
acquire	NULL
granulocyte-like	NULL
characteristics	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL
``	NULL

To	NULL
see	NULL
whether	NULL
IRF-1	NULL
mRNA	NULL
production	NULL
was	NULL
activated	NULL
by	NULL
ATRA	NULL
in	NULL
HL-60	NULL
cells	NULL
as	NULL
in	NULL
NB4	NULL
cells	NULL
,	NULL
we	NULL
treated	NULL
HL-60	NULL
cells	NULL
with	NULL
1	NULL
mol/L	NULL
ATRA	NULL
,	NULL
collected	NULL
cells	NULL
at	NULL
different	NULL
time	NULL
points	NULL
after	NULL
induction	NULL
,	NULL
and	NULL
analyzed	NULL
steady-state	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
by	NULL
Northern	NULL
blotting	NULL
.	NULL

IRF-1	NULL
mRNA	NULL
levels	NULL
were	NULL
clearly	NULL
elevated	NULL
already	NULL
1	NULL
hour	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
,	NULL
and	NULL
at	NULL
3	NULL
hours	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
were	NULL
approximately	NULL
threefold	NULL
and	NULL
eightfold	NULL
higher	NULL
as	NULL
compared	NULL
with	NULL
basal	NULL
levels	NULL
in	NULL
HL-60	NULL
and	NULL
NB4	NULL
cells	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
analyzed	NULL
by	NULL
densitometric	NULL
scanning	NULL
.	NULL

IRF-1	NULL
mRNA	NULL
levels	NULL
are	NULL
rapidly	NULL
upregulated	NULL
by	NULL
ATRA	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

To	NULL
see	NULL
whether	NULL
induction	NULL
of	NULL
IRF-1	NULL
gene	NULL
expression	NULL
by	NULL
ATRA	NULL
is	NULL
also	NULL
a	NULL
common	NULL
feature	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
ATRA	NULL
on	NULL
steady-state	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
in	NULL
THP-1	NULL
and	NULL
U937	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
human	NULL
primary	NULL
macrophages	NULL
.	NULL

THP-1	NULL
and	NULL
U937	NULL
cells	NULL
are	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
committed	NULL
for	NULL
monocytic	NULL
differentiation	NULL
,	NULL
and	NULL
they	NULL
acquire	NULL
a	NULL
more	NULL
monocytic	NULL
phenotype	NULL
in	NULL
response	NULL
to	NULL
treatment	NULL
with	NULL
ATRA	NULL
.	NULL
``	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
``	NULL
mRNA	NULL
showed	NULL
that	NULL
basal	NULL
levels	NULL
of	NULL
IRF-1	NULL
mRNA	NULL
were	NULL
readily	NULL
detectable	NULL
in	NULL
THP-1	NULL
cells	NULL
.	NULL

As	NULL
in	NULL
NB4	NULL
and	NULL
HL-60	NULL
cells	NULL
(	NULL
Figs	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
increased	NULL
starting	NULL
from	NULL
1	NULL
hour	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
whereas	NULL
IRF-2	NULL
gene	NULL
expression	NULL
showed	NULL
slower	NULL
kinetics	NULL
of	NULL
activation	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

Sim-ilarly	NULL
,	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
isolated	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

RETINOIC	NULL
ACID	NULL
ACTIVATES	NULL
IRF-1	NULL
GENE	NULL
EXPRESSION	NULL
&	NULL
Â£	NULL
Â£	NULL
e	NULL
-	NULL
E	NULL
&	NULL
â¬	NULL
Â§	NULL
f	NULL
o	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
4	NULL
b	NULL
â¬oo	NULL
cc	NULL
cC	NULL
[	NULL
re	NULL
+	NULL
#	NULL
â	NULL
Â»	NULL
``	NULL
RFA	NULL
@	NULL
-	NULL
waa	NULL
ann	NULL
wo	NULL
ap	NULL
.	NULL

%	NULL
n	NULL
ae	NULL
to	NULL
to	NULL
ar	NULL
an	NULL
GAPDH	NULL
IRF-1	NULL
IRF-2	NULL
4	NULL
|	NULL
Relative	NULL
steady-state	NULL
mRNA	NULL
level	NULL
0	NULL
1	NULL
3	NULL
6	NULL
24	NULL
0	NULL
72	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Fig	NULL
3	NULL
.	NULL

Expression	NULL
of	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
genes	NULL
in	NULL
THP-1	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
mol/L	NULL
ATRA	NULL
and	NULL
then	NULL
collected	NULL
,	NULL
and	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
was	NULL
isolated	NULL
.	NULL

Samples	NULL
(	NULL
5	NULL
ug	NULL
mRNA	NULL
)	NULL
were	NULL
fractionated	NULL
on	NULL
agarose	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
,	NULL
and	NULL
then	NULL
hybridized	NULL
to	NULL
the	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
cDNA	NULL
probes	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
also	NULL
hybridized	NULL
to	NULL
a	NULL
constant	NULL
probe	NULL
(	NULL
GAPDH	NULL
)	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
RNA	NULL
loading	NULL
in	NULL
each	NULL
lane	NULL
was	NULL
equal	NULL
.	NULL

from	NULL
U937	NULL
cells	NULL
and	NULL
human	NULL
macrophages	NULL
indicated	NULL
that	NULL
ATRA	NULL
also	NULL
rapidly	NULL
activates	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
densitometric	NULL
scanning	NULL
,	NULL
a	NULL
sevenfold	NULL
induction	NULL
(	NULL
U937	NULL
cells	NULL
)	NULL
and	NULL
2.5-fold	NULL
induction	NULL
(	NULL
human	NULL
macro-phages	NULL
)	NULL
was	NULL
seen	NULL
2	NULL
hours	NULL
after	NULL
ATRA	NULL
treatment	NULL
as	NULL
compared	NULL
with	NULL
basal	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
ATRA	NULL
also	NULL
directly	NULL
upregulates	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
committed	NULL
for	NULL
monocytic	NULL
differentiation	NULL
,	NULL
and	NULL
also	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
in	NULL
primary	NULL
macrophages	NULL
.	NULL

ATRA	NULL
activates	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
protein	NULL
synthesis	NULL
.	NULL

-	NULL
To	NULL
study	NULL
whether	NULL
ongoing	NULL
protein	NULL
synthesis	NULL
was	NULL
required	NULL
for	NULL
ATRA-induced	NULL
IRF-1	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
treated	NULL
NB4	NULL
cells	NULL
with	NULL
ATRA	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
cycloheximide	NULL
.	NULL

The	NULL
concentration	NULL
used	NULL
(	NULL
100	NULL
g/	NULL
mL	NULL
)	NULL
is	NULL
capable	NULL
of	NULL
fully	NULL
blocking	NULL
protein	NULL
synthesis	NULL
in	NULL
human	NULL
leukocytes	NULL
.	NULL
``	NULL

NB4	NULL
cells	NULL
were	NULL
collected	NULL
at	NULL
2	NULL
hours	NULL
posttreat-	NULL
117	NULL
ment	NULL
,	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
,	NULL
and	NULL
steady-state	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
were	NULL
analyzed	NULL
by	NULL
Northern	NULL
blotting	NULL
.	NULL

Even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cycloheximide	NULL
,	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
were	NULL
strongly	NULL
elevated	NULL
by	NULL
ATRA	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
IRF-1	NULL
gene	NULL
is	NULL
a	NULL
primary	NULL
target	NULL
gene	NULL
for	NULL
ATRA	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
observations	NULL
,	NULL
``	NULL
*	NULL
``	NULL
Â®	NULL
cycloheximide	NULL
treatment	NULL
of	NULL
cells	NULL
resulted	NULL
in	NULL
slightly	NULL
higher	NULL
steady-state	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
as	NULL
compared	NULL
with	NULL
control	NULL
cells	NULL
.	NULL

Effect	NULL
of	NULL
ATRA	NULL
on	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
occurs	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

_	NULL
To	NULL
further	NULL
study	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IRF-1	NULL
gene	NULL
by	NULL
ATRA	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
nuclear	NULL
runoff	NULL
analysis	NULL
.	NULL

Figure	NULL
6	NULL
shows	NULL
that	NULL
the	NULL
IRF-1	NULL
gene	NULL
transcription	NULL
rate	NULL
was	NULL
greatly	NULL
enhanced	NULL
at	NULL
1	NULL
hour	NULL
after	NULL
ATRA	NULL
treatment	NULL
and	NULL
rapidly	NULL
diminished	NULL
thereafter	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
ele-	NULL
A	NULL
uss	NULL
?	NULL

Time	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
hours	NULL
)	NULL
0	NULL
_	NULL
2	NULL
8	NULL
24	NULL
48	NULL
72	NULL
<	NULL
-	NULL
IRF-1	NULL
mRNA	NULL
<	NULL
-	NULL
GAPDH	NULL
mRNA	NULL
B	NULL
Macrophages	NULL
Time	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
hours	NULL
)	NULL
<	NULL
-	NULL
IRF-1	NULL
mRNA	NULL
<	NULL
-	NULL
GAPDH	NULL
mRNA	NULL
Fig	NULL
4	NULL
.	NULL

_	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
are	NULL
rapidly	NULL
upregulated	NULL
by	NULL
ATRA	NULL
in	NULL
U937	NULL
cells	NULL
and	NULL
in	NULL
human	NULL
macrophages	NULL
.	NULL

Human	NULL
monocytes	NULL
were	NULL
isolated	NULL
,	NULL
and	NULL
adherent	NULL
cells	NULL
were	NULL
grown	NULL
for	NULL
1	NULL
week	NULL
in	NULL
Macrophage-SFM	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
.	NULL

U937	NULL
cells	NULL
and	NULL
human	NULL
primary	NULL
macrophages	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
mol/L	NULL
ATRA	NULL
,	NULL
after	NULL
which	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
total	NULL
cellular	NULL
RNA	NULL
isolated	NULL
.	NULL

Samples	NULL
(	NULL
30	NULL
ug	NULL
)	NULL
were	NULL
fractionated	NULL
on	NULL
agarose	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
,	NULL
and	NULL
then	NULL
hybridized	NULL
to	NULL
the	NULL
IRF-1	NULL
and	NULL
GAPDH	NULL
cDNA	NULL
probes	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

<	NULL
CC	NULL
<	NULL
I	NULL
+	NULL
â¬	NULL
-C	NULL
O	NULL
118	NULL
CHX	NULL
ATRA	NULL
IRF-1	NULL
caron	NULL
-	NULL
Wii	NULL
os	NULL
cae	NULL
wal	NULL
Fig	NULL
5	NULL
.	NULL

ATRA	NULL
induced	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
protein	NULL
synthesis	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
mol/L	NULL
ATRA	NULL
for	NULL
2	NULL
hours	NULL
,	NULL
after	NULL
which	NULL
they	NULL
were	NULL
collected	NULL
and	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
.	NULL

Cycloheximide	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
was	NULL
added	NULL
30	NULL
minutes	NULL
before	NULL
ATRA	NULL
stimulation	NULL
.	NULL

Samples	NULL
(	NULL
30	NULL
ug	NULL
)	NULL
were	NULL
fractionated	NULL
on	NULL
agarose	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
,	NULL
and	NULL
then	NULL
hybridized	NULL
to	NULL
the	NULL
IRF-1	NULL
and	NULL
GAPDH	NULL
cDNA	NULL
probes	NULL
.	NULL

vated	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
in	NULL
ATRA-treated	NULL
cells	NULL
are	NULL
at	NULL
least	NULL
partly	NULL
due	NULL
to	NULL
an	NULL
increased	NULL
IRF-1	NULL
gene	NULL
transcription	NULL
rate	NULL
.	NULL

ATRA	NULL
activates	NULL
IRF-1	NULL
protein	NULL
expression	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

To	NULL
see	NULL
whether	NULL
the	NULL
increased	NULL
IRF-1	NULL
gene	NULL
expression	NULL
would	NULL
also	NULL
lead	NULL
to	NULL
corresponding	NULL
increases	NULL
in	NULL
the	NULL
respective	NULL
protein	NULL
levels	NULL
,	NULL
we	NULL
performed	NULL
Western	NULL
blot	NULL
analyses	NULL
with	NULL
IRF-1-specific	NULL
antibodies	NULL
.	NULL

IRF-1	NULL
protein	NULL
levels	NULL
are	NULL
already	NULL
higher	NULL
2	NULL
hours	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
indicating	NULL
that	NULL
elevated	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
also	NULL
lead	NULL
to	NULL
higher	NULL
intracellular	NULL
levels	NULL
of	NULL
IRF-1	NULL
protein	NULL
(	NULL
Fig	NULL
7	NULL
)	NULL
.	NULL

IFN-induced	NULL
IRF-1	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

To	NULL
study	NULL
in	NULL
more	NULL
detail	NULL
the	NULL
kinetics	NULL
of	NULL
IFN-a	NULL
Â«	NULL
-	NULL
and	NULL
IFN-y-induced	NULL
IRF-1	NULL
mRNA	NULL
expression	NULL
,	NULL
we	NULL
treated	NULL
NB4	NULL
cells	NULL
with	NULL
IFN-a	NULL
(	NULL
1,000	NULL
IU/mL	NULL
)	NULL
and	NULL
IFN-y	NULL
(	NULL
100	NULL
IU/mL	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
and	NULL
analyzed	NULL
IRF-1	NULL
mRNA	NULL
expression	NULL
.	NULL

Both	NULL
IFN-a	NULL
(	NULL
1,000	NULL
IU/mL	NULL
)	NULL
and	NULL
IFN-y	NULL
(	NULL
100	NULL
IU/mL	NULL
)	NULL
induced	NULL
IRF-1	NULL
mRNA	NULL
expression	NULL
2	NULL
hours	NULL
postinduction	NULL
(	NULL
Fig	NULL
10A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
kinetics	NULL
of	NULL
IFN-	NULL
Â«	NULL
-	NULL
and	NULL
IFN-y-induced	NULL
mRNA	NULL
expression	NULL
was	NULL
significantly	NULL
different	NULL
.	NULL

IFN-	NULL
Â«	NULL
induced	NULL
a	NULL
transient	NULL
IRF-1	NULL
mRNA	NULL
expression	NULL
,	NULL
whereas	NULL
IFN-y-induced	NULL
IRF-1	NULL
mRNA	NULL
stayed	NULL
at	NULL
constant	NULL
elevated	NULL
levels	NULL
up	NULL
to	NULL
24	NULL
hours	NULL
(	NULL
Fig	NULL
8A	NULL
)	NULL
.	NULL

To	NULL
see	NULL
whether	NULL
IFN-	NULL
Â«	NULL
-	NULL
and	NULL
IFN-y-induced	NULL
IRF-1	NULL
MATIKAINEN	NULL
ET	NULL
AL	NULL
mRNA	NULL
levels	NULL
would	NULL
also	NULL
lead	NULL
to	NULL
corresponding	NULL
increases	NULL
in	NULL
the	NULL
respective	NULL
protein	NULL
levels	NULL
,	NULL
we	NULL
performed	NULL
Western	NULL
blot	NULL
analyses	NULL
with	NULL
specific	NULL
anti-IRF-1	NULL
antibodies	NULL
.	NULL

Protein	NULL
levels	NULL
are	NULL
already	NULL
higher	NULL
2	NULL
hours	NULL
after	NULL
IFN-a	NULL
and	NULL
IFN-y	NULL
treatment	NULL
,	NULL
indicating	NULL
that	NULL
IFN-induced	NULL
elevated	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
lead	NULL
to	NULL
higher	NULL
intracellular	NULL
levels	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
(	NULL
Fig	NULL
10B	NULL
)	NULL
.	NULL

Elevated	NULL
IRF-1	NULL
protein	NULL
levels	NULL
were	NULL
observed	NULL
after	NULL
both	NULL
IFN-a	NULL
and	NULL
IFN-y	NULL
induction	NULL
and	NULL
appeared	NULL
to	NULL
persist	NULL
up	NULL
to	NULL
72	NULL
hours	NULL
(	NULL
Fig	NULL
8B	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
IFN-a	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
ATRA	NULL
on	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
and	NULL
NF-kB	NULL
DNA-binding	NULL
activities	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
is	NULL
primarily	NULL
controlled	NULL
by	NULL
STAT	NULL
and	NULL
IRF	NULL
transcription	NULL
factors	NULL
.	NULL

IFN-a	NULL
and	NULL
especially	NULL
IFN-y	NULL
are	NULL
able	NULL
to	NULL
activate	NULL
and	NULL
induce	NULL
the	NULL
binding	NULL
of	NULL
STAT	NULL
1a	NULL
to	NULL
GAS	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
IFN-y-inducible	NULL
genes	NULL
,	NULL
``	NULL
such	NULL
as	NULL
IRF-1.5Â°	NULL
Since	NULL
ATRA	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
NB4	NULL
cells	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
analyze	NULL
whether	NULL
ATRA	NULL
is	NULL
able	NULL
to	NULL
induce	NULL
GAS	NULL
DNA-binding	NULL
activity	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

We	NULL
also	NULL
stimulated	NULL
NB4	NULL
cells	NULL
with	NULL
high-dose	NULL
IFN-a	NULL
(	NULL
1,000	NULL
IU/mL	NULL
)	NULL
and	NULL
IFN-y	NULL
(	NULL
1,000	NULL
IU/mL	NULL
)	NULL
and	NULL
studied	NULL
the	NULL
GAS	NULL
DNA-binding	NULL
activities	NULL
.	NULL

IFN-a	NULL
induced	NULL
a	NULL
transient	NULL
increase	NULL
in	NULL
GAS	NULL
DNA-binding	NULL
activity	NULL
,	NULL
with	NULL
maximal	NULL
activity	NULL
seen	NULL
at	NULL
30	NULL
minutes	NULL
(	NULL
Fig	NULL
9	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
IFN-y	NULL
stimulation	NULL
of	NULL
NB4	NULL
cells	NULL
resulted	NULL
in	NULL
a	NULL
stable	NULL
GAS	NULL
DNA-binding	NULL
activity	NULL
that	NULL
was	NULL
still	NULL
clearly	NULL
visible	NULL
at	NULL
24	NULL
hours	NULL
postinduction	NULL
.	NULL

We	NULL
also	NULL
used	NULL
a	NULL
high-affinity	NULL
SIE	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
EMSA	NULL
,	NULL
since	NULL
the	NULL
SIE	NULL
sequence	NULL
also	NULL
binds	NULL
IFN-	NULL
Â«	NULL
-	NULL
and	NULL
IFN-y-activated	NULL
transcription	NULL
factor	NULL
STAT3	NULL
(	NULL
and	NULL
STAT1a	NULL
)	NULL
.	NULL
``	NULL

IFN-a	NULL
Â«	NULL
-	NULL
and	NULL
IFN-y-induced	NULL
SIE	NULL
DNA-binding	NULL
activity	NULL
was	NULL
kinetically	NULL
and	NULL
qualitatively	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
by	NULL
the	NULL
GAS	NULL
probe	NULL
(	NULL
Fig	NULL
9	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
cells	NULL
with	NULL
ATRA	NULL
for	NULL
different	NULL
times	NULL
and	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
for	NULL
GAS	NULL
or	NULL
SIE	NULL
DNA-binding	NULL
activity	NULL
(	NULL
Fig	NULL
10	NULL
)	NULL
suggested	NULL
that	NULL
STAT	NULL
proteins	NULL
are	NULL
unlikely	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
ATRA-induced	NULL
IRF-1	NULL
,	NULL
IRF-2	NULL
,	NULL
or	NULL
OAS	NULL
gene	NULL
expression	NULL
,	NULL
since	NULL
no	NULL
enhanced	NULL
DNA-binding	NULL
was	NULL
observed	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
NF-	NULL
Â«	NULL
B	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

For	NULL
example	NULL
,	NULL
TNF-a	NULL
,	NULL
a	NULL
known	NULL
activator	NULL
of	NULL
NF-KB	NULL
,	NULL
is	NULL
able	NULL
to	NULL
induce	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
many	NULL
types	NULL
of	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
and	NULL
NF-KB	NULL
binding	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
IRF-1	NULL
gene	NULL
.	NULL
``	NULL

To	NULL
study	NULL
whether	NULL
ATRA	NULL
is	NULL
able	NULL
to	NULL
induce	NULL
activation	NULL
of	NULL
NF-kB	NULL
in	NULL
NB4	NULL
cells	NULL
,	NULL
Time	NULL
after	NULL
ATRA	NULL
treatment	NULL
0-1	NULL
1th	NULL
2h	NULL
_	NULL
O-II	NULL
j	NULL
<	NULL
-	NULL
IRF-1	NULL
mRNA	NULL
@	NULL
'	NULL
lua	NULL
'	NULL
<	NULL
-	NULL
B-actin	NULL
mRNA	NULL
Fig	NULL
6	NULL
.	NULL

-	NULL
Nuclear	NULL
runoff	NULL
analysis	NULL
of	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
ATRA-treated	NULL
NB4	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
pmol/L	NULL
ATRA	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
and	NULL
nuclei	NULL
were	NULL
isolated	NULL
.	NULL

Nuclear	NULL
run-off	NULL
analysis	NULL
was	NULL
performed	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

RETINOIC	NULL
ACID	NULL
ACTIVATES	NULL
IRF-1	NULL
GENE	NULL
EXPRESSION	NULL
119	NULL
Time	NULL
after	NULL
ATRA	NULL
treatment	NULL
(	NULL
hours	NULL
)	NULL
kDa	NULL
Fig	NULL
7	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
IRF-1	NULL
protein	NULL
expression	NULL
in	NULL
ATRA-treated	NULL
NB4	NULL
cells	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
pmol/L	NULL
ATRA	NULL
,	NULL
after	NULL
which	NULL
cells	NULL
were	NULL
collected	NULL
at	NULL
the	NULL
time	NULL
points	NULL
indicated	NULL
.	NULL

Protein	NULL
samples	NULL
(	NULL
30	NULL
ug	NULL
)	NULL
were	NULL
separated	NULL
on	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
Western	NULL
blots	NULL
were	NULL
stained	NULL
with	NULL
IRF-1-specific	NULL
antibodies	NULL
.	NULL

In	NULL
vitro	NULL
(	NULL
In	NULL
v.	NULL
)	NULL
translated	NULL
IRF-1	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

80	NULL
49	NULL
we	NULL
performed	NULL
EMSAs	NULL
with	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
consensus	NULL
NF-	NULL
Â«	NULL
kB	NULL
DNA-binding	NULL
site	NULL
.	NULL

TNF-a	NULL
,	NULL
which	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
,	NULL
induced	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
in	NULL
NB4	NULL
cells	NULL
(	NULL
Fig	NULL
10	NULL
)	NULL
,	NULL
whereas	NULL
ATRA	NULL
did	NULL
not	NULL
increase	NULL
any	NULL
NF-	NULL
Â«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
NF-KB	NULL
is	NULL
most	NULL
likely	NULL
not	NULL
involved	NULL
in	NULL
ATRA-induced	NULL
activation	NULL
of	NULL
IRF-1	NULL
,	NULL
IRF-2	NULL
,	NULL
or	NULL
OAS	NULL
genes	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

Basal	NULL
NF-kB	NULL
DNA-binding	NULL
instead	NULL
seemed	NULL
to	NULL
decrease	NULL
during	NULL
ATRA	NULL
treatment	NULL
(	NULL
Fig	NULL
10	NULL
)	NULL
.	NULL

Synergistic	NULL
activation	NULL
of	NULL
IRF-1	NULL
gene	NULL
expression	NULL
by	NULL
ATRA	NULL
and	NULL
IFN-y	NULL
.	NULL

-	NULL
Since	NULL
ATRA	NULL
can	NULL
induce	NULL
IRF-1	NULL
gene	NULL
expression	NULL
by	NULL
a	NULL
pathway	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
STAT-	NULL
or	NULL
NF-	NULL
Â«	NULL
B-mediated	NULL
pathways	NULL
(	NULL
Fig	NULL
10	NULL
)	NULL
,	NULL
we	NULL
studied	NULL
whether	NULL
ATRA	NULL
synergistically	NULL
or	NULL
additively	NULL
increased	NULL
IFN-y-activated	NULL
IRF-1	NULL
gene	NULL
expression	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
treated	NULL
NB4	NULL
cells	NULL
with	NULL
low-dose	NULL
IFN-y	NULL
(	NULL
1	NULL
or	NULL
10	NULL
IU/mL	NULL
)	NULL
with	NULL
or	NULL
without	NULL
ATRA	NULL
and	NULL
analyzed	NULL
steady-state	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
at	NULL
3	NULL
hours	NULL
postinduction	NULL
(	NULL
Fig	NULL
11	NULL
)	NULL
.	NULL

ATRA	NULL
alone	NULL
induced	NULL
the	NULL
IRF-1	NULL
gene	NULL
at	NULL
levels	NULL
comparable	NULL
to	NULL
those	NULL
induced	NULL
by	NULL
1	NULL
IU/mL	NULL
IFN-y	NULL
.	NULL

With	NULL
different	NULL
doses	NULL
of	NULL
IFN-y	NULL
(	NULL
1	NULL
and	NULL
10	NULL
IU/mL	NULL
)	NULL
,	NULL
there	NULL
appeared	NULL
to	NULL
be	NULL
a	NULL
more	NULL
than	NULL
additive	NULL
effect	NULL
with	NULL
ATRA	NULL
(	NULL
Fig	NULL
11	NULL
)	NULL
on	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
.	NULL

A	NULL
B	NULL
kDa	NULL
Inv	NULL
.	NULL

0	NULL
2	NULL
IFN-a	NULL
IFN-y	NULL
8	NULL
24	NULL
48	NULL
72	NULL
2	NULL
8	NULL
24	NULL
48	NULL
72	NULL
O-lI	NULL
Â¥	NULL
Inv	NULL
.	NULL

0	NULL
2	NULL
8	NULL
24	NULL
48	NULL
72	NULL
4	NULL
<	NULL
-	NULL
protein	NULL
\_	NULL
IRF	NULL
protein	NULL
DISCUSSION	NULL
Retinoid	NULL
acids	NULL
and	NULL
IFNs	NULL
are	NULL
potent	NULL
regulatory	NULL
molecules	NULL
.	NULL

They	NULL
can	NULL
inhibit	NULL
cellular	NULL
proliferation	NULL
,	NULL
and	NULL
they	NULL
have	NULL
a	NULL
clear	NULL
differentiating	NULL
effect	NULL
on	NULL
cells	NULL
.	NULL

Relatively	NULL
little	NULL
is	NULL
known	NULL
about	NULL
retinoic	NULL
acid-induced	NULL
target	NULL
genes	NULL
that	NULL
would	NULL
be	NULL
involved	NULL
in	NULL
regulating	NULL
cellular	NULL
proliferation	NULL
and	NULL
differentiation	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
IFNs	NULL
,	NULL
more	NULL
information	NULL
is	NULL
available	NULL
and	NULL
several	NULL
genes	NULL
directly	NULL
regulated	NULL
by	NULL
IFNs	NULL
have	NULL
been	NULL
associated	NULL
with	NULL
inhibition	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

IRF-1	NULL
and	NULL
IRF-2	NULL
,	NULL
transcription	NULL
activator	NULL
and	NULL
repressor	NULL
,	NULL
respectively	NULL
,	NULL
have	NULL
linked	NULL
the	NULL
IFN	NULL
system	NULL
directly	NULL
to	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

The	NULL
levels	NULL
and	NULL
ratios	NULL
of	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
mRNA	NULL
and	NULL
protein	NULL
fluctuate	NULL
during	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

IRF-1	NULL
levels	NULL
are	NULL
lowest	NULL
during	NULL
growth	NULL
stimulation	NULL
and	NULL
highest	NULL
at	NULL
growth	NULL
arrest	NULL
.	NULL
``	NULL

Experiments	NULL
with	NULL
IRF-1~~	NULL
cells	NULL
obtained	NULL
from	NULL
knockout	NULL
mice	NULL
suggest	NULL
that	NULL
IRF-1	NULL
is	NULL
an	NULL
antioncogenic	NULL
protein	NULL
and	NULL
is	NULL
also	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

**~*	NULL
In	NULL
addition	NULL
,	NULL
IRF-1	NULL
protein	NULL
can	NULL
counteract	NULL
cellular	NULL
transformation	NULL
induced	NULL
by	NULL
IRF-2	NULL
overexpression	NULL
.	NULL
``	NULL

The	NULL
present	NULL
knowledge	NULL
of	NULL
IRF-1	NULL
protein	NULL
suggests	NULL
that	NULL
it	NULL
is	NULL
tightly	NULL
linked	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

However	NULL
,	NULL
some	NULL
other	NULL
factors	NULL
such	NULL
as	NULL
IFN-inducible	NULL
PKR	NULL
and	NULL
RNAase	NULL
L	NULL
molecule	NULL
of	NULL
the	NULL
OAS/RNAase	NULL
L	NULL
pathway	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
function	NULL
Time	NULL
after	NULL
IFN	NULL
treatment	NULL
,	NULL
1000	NULL
IU/m	NULL
!	NULL

(	NULL
hours	NULL
)	NULL
<	NULL
-	NULL
IRF-1	NULL
mRNA	NULL
Fig	NULL
8	NULL
.	NULL

IFN-induced	NULL
IRF-1	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
NB4	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFN-	NULL
Â«	NULL
or	NULL
IFN-y	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
after	NULL
which	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
,	NULL
and	NULL
30-ug	NULL
samples	NULL
were	NULL
separated	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gels	NULL
.	NULL

After	NULL
transfer	NULL
to	NULL
nylon	NULL
membrane	NULL
,	NULL
the	NULL
filter	NULL
was	NULL
hybridized	NULL
with	NULL
IRF-1	NULL
and	NULL
GAPDH	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
cDNA	NULL
probes	NULL
.	NULL

(	NULL
B	NULL
)	NULL
NB4	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
IFN-	NULL
Â«	NULL
(	NULL
1,000	NULL
IU/mL	NULL
)	NULL
or	NULL
IFN-y	NULL
(	NULL
1,000	NULL
IU/mL	NULL
)	NULL
,	NULL
after	NULL
which	NULL
cells	NULL
were	NULL
collected	NULL
at	NULL
the	NULL
time	NULL
points	NULL
indicated	NULL
.	NULL

Protein	NULL
samples	NULL
(	NULL
30	NULL
ug	NULL
)	NULL
were	NULL
separated	NULL
on	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
Western	NULL
blots	NULL
were	NULL
stained	NULL
with	NULL
IRF-1-specific	NULL
antibodies	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

120	NULL
IFN-o	NULL
IFN-y	NULL
@	NULL
&	NULL
Â£	NULL
<	NULL
Â£	NULL
&	NULL
ty	NULL
)	NULL
[	NULL
ty	NULL
]	NULL
2	NULL
3	NULL
&	NULL
&	NULL
&	NULL
4	NULL
Sf	NULL
f	NULL
&	NULL
a	NULL
GAS	NULL
-	NULL
UU	NULL
&	NULL
W	NULL
W	NULL
WW	NULL
Â»	NULL
ie	NULL
IFN-o	NULL
IFN-y	NULL
0	NULL
c	NULL
Â£	NULL
c	NULL
Â£	NULL
J	NULL
w	NULL
)	NULL
WU	NULL
2	NULL
o	NULL
Â£	NULL
&	NULL
6	NULL
Â§	NULL
sf	NULL
f	NULL
6	NULL
d	NULL
n	NULL
int	NULL
MSIE	NULL
J	NULL
,	NULL
gin	NULL
;	NULL
w	NULL
Fig	NULL
9	NULL
.	NULL

Effect	NULL
of	NULL
IFN-	NULL
Â«	NULL
and	NULL
IFN-y	NULL
on	NULL
GAS	NULL
and	NULL
SIE	NULL
DNA-binding	NULL
activities	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
with	NULL
1,000	NULL
IU/mL	NULL
IFN-	NULL
Â«	NULL
or	NULL
IFN-y	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
incubated	NULL
with	NULL
*	NULL
``	NULL
P-labeled	NULL
GAS	NULL
or	NULL
SIE	NULL
oligonucleotide	NULL
,	NULL
and	NULL
analyzed	NULL
in	NULL
EMSA	NULL
.	NULL

as	NULL
tumor	NULL
suppressor	NULL
genes	NULL
.	NULL

'*	NULL
``	NULL
Â°	NULL
In	NULL
the	NULL
present	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
in	NULL
promyelocytic	NULL
NB4	NULL
leukemia	NULL
cells	NULL
,	NULL
retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
can	NULL
directly	NULL
upregulate	NULL
IRF-1	NULL
gene	NULL
expression	NULL
.	NULL

The	NULL
increased	NULL
IRF-1	NULL
gene	NULL
expression	NULL
is	NULL
followed	NULL
by	NULL
increased	NULL
expression	NULL
of	NULL
other	NULL
IFN-inducible	NULL
genes	NULL
,	NULL
namely	NULL
IRF-2	NULL
and	NULL
OAS	NULL
,	NULL
but	NULL
with	NULL
clearly	NULL
slower	NULL
kinetics	NULL
.	NULL

Several	NULL
different	NULL
stimuli	NULL
may	NULL
enhance	NULL
IRF-1	NULL
gene	NULL
expression	NULL
.	NULL

Viruses	NULL
,	NULL
``	NULL
*	NULL
``	NULL
``	NULL
dsRNA	NULL
,	NULL
IFNs	NULL
,	NULL
and	NULL
several	NULL
other	NULL
cyto-kines***	NULL
'	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
directly	NULL
transcriptionally	NULL
activate	NULL
IRF-1	NULL
gene	NULL
expression	NULL
.	NULL

Detailed	NULL
analysis	NULL
of	NULL
the	NULL
IRF-1	NULL
promoter**	NULL
``	NULL
has	NULL
shown	NULL
that	NULL
the	NULL
promoter	NULL
has	NULL
a	NULL
functional	NULL
GAS	NULL
element	NULL
(	NULL
at	NULL
position	NULL
-120	NULL
)	NULL
that	NULL
is	NULL
bound	NULL
by	NULL
activated	NULL
STAT	NULL
1a	NULL
.	NULL
``	NULL

Pine	NULL
et	NULL
al	NULL
``	NULL
Â®	NULL
recently	NULL
(	NULL
1994	NULL
)	NULL
also	NULL
showed	NULL
by	NULL
using	NULL
IRF-1	NULL
promoter	NULL
reporter	NULL
constructs	NULL
that	NULL
in	NULL
HeLa	NULL
cells	NULL
IFN-y	NULL
induces	NULL
an	NULL
eightfold	NULL
increase	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
a	NULL
twofold	NULL
increase	NULL
with	NULL
IFN-	NULL
.	NULL

Consistent	NULL
with	NULL
these	NULL
promoter	NULL
studies	NULL
,	NULL
we	NULL
also	NULL
observed	NULL
that	NULL
in	NULL
NB4	NULL
cells	NULL
IFN-y	NULL
was	NULL
a	NULL
much	NULL
better	NULL
inducer	NULL
of	NULL
IRF-1	NULL
gene	NULL
expression	NULL
than	NULL
IFN-	NULL
.	NULL

IL-6	NULL
can	NULL
activate	NULL
the	NULL
transcription	NULL
factor	NULL
STAT3	NULL
,	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
degree	NULL
STAT1a	NULL
.	NULL

``	NULL
``	NULL
``	NULL
*Â°	NULL
It	NULL
was	NULL
recently	NULL
shown	NULL
that	NULL
IL-6-induced	NULL
IRF-1	NULL
gene	NULL
expression	NULL
is	NULL
mediated	NULL
via	NULL
a	NULL
GAS	NULL
element	NULL
but	NULL
also	NULL
via	NULL
another	NULL
closely	NULL
related	NULL
sequence	NULL
element	NULL
,	NULL
pIRE	NULL
.	NULL
``	NULL

IL-1	NULL
and	NULL
TNF-a	NULL
can	NULL
also	NULL
upregulate	NULL
IRF-1	NULL
gene	NULL
expres-sion	NULL
,	NULL
``	NULL
'	NULL
but	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
this	NULL
activation	NULL
have	NULL
not	NULL
been	NULL
revealed	NULL
so	NULL
far	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
activated	NULL
MATIKAINEN	NULL
ET	NULL
AL	NULL
shes	NULL
n	NULL
ig	NULL
ï¬zcssc	NULL
â	NULL
d	NULL
2	NULL
o	NULL
-	NULL
a	NULL
w	NULL
a	NULL
$	NULL
;	NULL
-o	NULL
<	NULL
4	NULL
4	NULL
4	NULL
4	NULL
4	NULL
Z	NULL
2	NULL
2	NULL
C	NULL
C	NULL
Â£	NULL
E	NULL
E	NULL
&	NULL
&	NULL
Id	NULL
ws	NULL
==	NULL
was	NULL
â	NULL
Wang	NULL
's	NULL
2	NULL
o	NULL
-	NULL
~	NULL
6	NULL
a	NULL
o	NULL
<	NULL
4	NULL
4G	NULL
4G	NULL
4G	NULL
<	NULL
4	NULL
2	NULL
C	NULL
-C	NULL
C	NULL
C	NULL
C	NULL
t	NULL
KZ	NULL
ren-	NULL
0.5h	NULL
[	NULL
Â®	NULL
)	NULL
J	NULL
>	NULL
UM	NULL
&	NULL
Â§	NULL
irs	NULL
0.5h	NULL
<	NULL
-	NULL
<	NULL
PR	NULL
UM	NULL
e	NULL
g	NULL
c	NULL
g	NULL
$	NULL
g	NULL
C	NULL
[	NULL
Â«	NULL
Â»	NULL
]	NULL
~-	NULL
N	NULL
&	NULL
N	NULL
LW	NULL
.	NULL

L.	NULL
o	NULL
<	NULL
4	NULL
4G	NULL
4G	NULL
4G	NULL
4d	NULL
z	NULL
z	NULL
z	NULL
C	NULL
C	NULL
C	NULL
C	NULL
C	NULL
iE	NULL
f	NULL
NF-xB	NULL
L	NULL
bp	NULL
but	NULL
i=	NULL
Fig	NULL
10	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
ATRA	NULL
on	NULL
GAS	NULL
,	NULL
SIE	NULL
,	NULL
and	NULL
NF-	NULL
Â«	NULL
B	NULL
DNA-binding	NULL
activities	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
ATRA	NULL
(	NULL
1	NULL
mol/L	NULL
)	NULL
,	NULL
IFNs	NULL
(	NULL
1,000	NULL
IU/mL	NULL
)	NULL
,	NULL
or	NULL
TNF-a	NULL
(	NULL
5	NULL
ng/mL	NULL
)	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
incubated	NULL
with	NULL
P-labeled	NULL
GAS	NULL
,	NULL
SIE	NULL
,	NULL
or	NULL
NF-xB	NULL
oligonucleotides	NULL
,	NULL
and	NULL
analyzed	NULL
in	NULL
EMSA	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

RETINOIC	NULL
ACID	NULL
ACTIVATES	NULL
IRF-1	NULL
GENE	NULL
EXPRESSION	NULL
IFN-y	NULL
10	NULL
1U/m	NULL
!	NULL

IFN-y	NULL
1	NULL
1U/m	NULL
!	NULL

IFN-y	NULL
10	NULL
1U/m	NULL
!	NULL

+	NULL
RA	NULL
IFN-y	NULL
1	NULL
1U/m	NULL
!	NULL

+	NULL
RA	NULL
@	NULL
Â£	NULL
o	NULL
2	NULL
RA	NULL
IRF-1	NULL
GAPDH	NULL
IRF-1	NULL
mRNA	NULL
Fig	NULL
11	NULL
.	NULL

-	NULL
Synergistic	NULL
effect	NULL
of	NULL
IFN-y	NULL
and	NULL
ATRA	NULL
in	NULL
IRF-1	NULL
gene	NULL
expression	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFN-y	NULL
,	NULL
ATRA	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
2	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
3	NULL
hours	NULL
after	NULL
induction	NULL
,	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
,	NULL
and	NULL
30-ug	NULL
samples	NULL
were	NULL
separated	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gels	NULL
.	NULL

After	NULL
transfer	NULL
to	NULL
nylon	NULL
membrane	NULL
,	NULL
the	NULL
filter	NULL
was	NULL
hybridized	NULL
with	NULL
IRF-1	NULL
and	NULL
GAPDH	NULL
cDNAs	NULL
.	NULL

NF-KB	NULL
is	NULL
involved	NULL
in	NULL
IL-1/TNF-a	NULL
Â«	NULL
-activated	NULL
IRF-1	NULL
gene	NULL
expression	NULL
.	NULL

Herein	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
ATRA	NULL
induces	NULL
IRF-1	NULL
gene	NULL
expression	NULL
in	NULL
a	NULL
retinoic	NULL
acid-sensitive	NULL
,	NULL
promyelocytic	NULL
leukemia	NULL
NB4	NULL
cell	NULL
line	NULL
.	NULL

Similar	NULL
induction	NULL
,	NULL
although	NULL
weaker	NULL
,	NULL
was	NULL
also	NULL
seen	NULL
in	NULL
HL-60	NULL
,	NULL
THP-1	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
human	NULL
primary	NULL
macrophages	NULL
.	NULL

These	NULL
leukemic	NULL
cells	NULL
respond	NULL
to	NULL
ATRA	NULL
by	NULL
growth	NULL
inhibition	NULL
,	NULL
suggesting	NULL
that	NULL
IRF-1	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
mediating	NULL
growth-inhibitory	NULL
effects	NULL
of	NULL
ATRA	NULL
.	NULL

Elevated	NULL
IRF-1	NULL
mRNA	NULL
levels	NULL
were	NULL
seen	NULL
very	NULL
early	NULL
,	NULL
already	NULL
at	NULL
1	NULL
hour	NULL
after	NULL
ATRA	NULL
induction	NULL
,	NULL
suggesting	NULL
that	NULL
IRF-1	NULL
is	NULL
a	NULL
primary	NULL
target	NULL
gene	NULL
in	NULL
ATRA-induced	NULL
re-sponse	NULL
.	NULL

Induction	NULL
of	NULL
IRF-1	NULL
gene	NULL
expression	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
protein	NULL
synthesis	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
,	NULL
and	NULL
nuclear	NULL
runoff	NULL
experiments	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
also	NULL
indicated	NULL
direct	NULL
transcriptional	NULL
activation	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
IRF-1	NULL
gene	NULL
is	NULL
a	NULL
direct	NULL
target	NULL
for	NULL
ATRA-induced	NULL
gene	NULL
activation	NULL
.	NULL

This	NULL
observation	NULL
is	NULL
the	NULL
first	NULL
to	NULL
directly	NULL
link	NULL
ATRA	NULL
response	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
a	NULL
potentially	NULL
antioncogenic	NULL
gene	NULL
.	NULL

Analysis	NULL
of	NULL
known	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
cytokine	NULL
signaling	NULL
suggests	NULL
that	NULL
ATRA	NULL
does	NULL
not	NULL
induce	NULL
any	NULL
detectable	NULL
GAS	NULL
(	NULL
STAT1a	NULL
)	NULL
,	NULL
SIE	NULL
(	NULL
STAT3	NULL
and	NULL
STATla	NULL
)	NULL
,	NULL
or	NULL
NF-kB	NULL
DNA-binding	NULL
activities	NULL
(	NULL
Fig	NULL
9	NULL
)	NULL
.	NULL

This	NULL
strongly	NULL
argues	NULL
against	NULL
these	NULL
transcription	NULL
factors	NULL
'	NULL
being	NULL
involved	NULL
in	NULL
IRF-1	NULL
and	NULL
other	NULL
121	NULL
IFN-inducible	NULL
(	NULL
IRF-2	NULL
and	NULL
OAS	NULL
)	NULL
gene	NULL
expression	NULL
in	NULL
ATRA-induced	NULL
NB4	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
ATRA-induced	NULL
IRF-1	NULL
gene	NULL
expression	NULL
occurs	NULL
directly	NULL
via	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
bound	NULL
to	NULL
IRF-1	NULL
gene	NULL
promoter	NULL
,	NULL
and	NULL
is	NULL
thus	NULL
distinct	NULL
from	NULL
the	NULL
STAT	NULL
and	NULL
NF-kB	NULL
pathways	NULL
.	NULL

This	NULL
may	NULL
indeed	NULL
be	NULL
the	NULL
case	NULL
,	NULL
since	NULL
computer	NULL
analysis	NULL
indicated	NULL
a	NULL
putative	NULL
retinoic	NULL
acid	NULL
receptor	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
IRF-1	NULL
gene	NULL
(	NULL
from	NULL
-455	NULL
to	NULL
-440	NULL
)	NULL
.	NULL

Detailed	NULL
promoter	NULL
deletion	NULL
,	NULL
mutagenesis	NULL
,	NULL
and	NULL
transient-expression	NULL
experiments	NULL
will	NULL
reveal	NULL
whether	NULL
this	NULL
element	NULL
really	NULL
is	NULL
a	NULL
functional	NULL
retinoic	NULL
acid	NULL
receptor	NULL
binding	NULL
and	NULL
activation	NULL
site	NULL
.	NULL

IRF-1	NULL
protein	NULL
is	NULL
a	NULL
transcriptional	NULL
activator	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
at	NULL
least	NULL
IFN-/3	NULL
promoter	NULL
and	NULL
to	NULL
ISRE-like	NULL
elements	NULL
in	NULL
the	NULL
regulatory	NULL
regions	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

``	NULL
``	NULL
*	NULL
``	NULL
``	NULL
Possibly	NULL
upon	NULL
activation	NULL
or	NULL
if	NULL
IRF-1	NULL
concentration	NULL
in	NULL
the	NULL
cell	NULL
is	NULL
in-creased	NULL
,	NULL
it	NULL
can	NULL
outcompete	NULL
transcriptional	NULL
repressors	NULL
,	NULL
such	NULL
as	NULL
IRF-2	NULL
,	NULL
from	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
.	NULL
``	NULL

IRF-1	NULL
protein	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
number	NULL
of	NULL
genes	NULL
including	NULL
OAS	NULL
,	NULL
IRF-2	NULL
,	NULL
inducible	NULL
nitric	NULL
oxidase	NULL
synthetase	NULL
(	NULL
iNOS	NULL
)	NULL
,	NULL
guanylate-bind-ing	NULL
protein	NULL
(	NULL
GBP	NULL
)	NULL
,	NULL
and	NULL
major	NULL
histocompatibility	NULL
genes	NULL
,	NULL
all	NULL
of	NULL
which	NULL
are	NULL
under	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
IFNs	NULL
.	NULL

``	NULL
>	NULL
Â°	NULL
It	NULL
seems	NULL
to	NULL
be	NULL
absolutely	NULL
essential	NULL
at	NULL
least	NULL
for	NULL
the	NULL
transcription	NULL
of	NULL
GBP	NULL
and	NULL
iNOS	NULL
genes	NULL
.	NULL

``	NULL
``	NULL
``	NULL
Â°	NULL
In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
analyzed	NULL
gene	NULL
expression	NULL
of	NULL
IRF-2	NULL
and	NULL
OAS	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL

Unlike	NULL
IRF-1	NULL
,	NULL
which	NULL
was	NULL
activated	NULL
very	NULL
rapidly	NULL
,	NULL
already	NULL
within	NULL
1	NULL
hour	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
IRF-2	NULL
and	NULL
OAS	NULL
mRNA	NULL
levels	NULL
were	NULL
found	NULL
to	NULL
be	NULL
elevated	NULL
several	NULL
hours	NULL
later	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

IRF-2	NULL
mRNA	NULL
levels	NULL
were	NULL
found	NULL
to	NULL
be	NULL
elevated	NULL
starting	NULL
at	NULL
3	NULL
to	NULL
6	NULL
hours	NULL
after	NULL
ATRA	NULL
treatment	NULL
,	NULL
whereas	NULL
OAS	NULL
mRNA	NULL
levels	NULL
were	NULL
found	NULL
to	NULL
be	NULL
strongly	NULL
elevated	NULL
much	NULL
later	NULL
,	NULL
at	NULL
24	NULL
to	NULL
72	NULL
hours	NULL
after	NULL
ATRA	NULL
treatment	NULL
.	NULL

However	NULL
,	NULL
basal	NULL
OAS	NULL
mRNA	NULL
levels	NULL
were	NULL
undetectable	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
the	NULL
expression	NULL
fits	NULL
well	NULL
with	NULL
the	NULL
idea	NULL
that	NULL
IRF-2	NULL
and	NULL
possibly	NULL
also	NULL
OAS	NULL
gene	NULL
expression	NULL
is	NULL
enhanced	NULL
by	NULL
IRF-1	NULL
protein	NULL
.	NULL

IRF-2	NULL
gene	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
responsive	NULL
to	NULL
IFNs	NULL
.	NULL

``	NULL
``	NULL
*	NULL
``	NULL
IRF-2	NULL
promoter	NULL
analysis	NULL
has	NULL
also	NULL
revealed	NULL
a	NULL
functional	NULL
IRF-1	NULL
binding	NULL
site	NULL
and	NULL
IRF-1-dependent	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
respective	NULL
gene	NULL
.	NULL
``	NULL

In	NULL
ATRA-stimu-lated	NULL
NB4	NULL
cells	NULL
,	NULL
the	NULL
increased	NULL
IRF-2	NULL
gene	NULL
expression	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
lead	NULL
to	NULL
a	NULL
shutdown	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
,	NULL
since	NULL
steady-state	NULL
OAS	NULL
mRNA	NULL
levels	NULL
were	NULL
in	NULL
fact	NULL
increased	NULL
during	NULL
follow-up	NULL
evaluation	NULL
.	NULL

ATRA	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
effective	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
APL	NULL
.	NULL

It	NULL
induces	NULL
an	NULL
irreversible	NULL
commitment	NULL
of	NULL
cells	NULL
to	NULL
differentiate	NULL
,	NULL
and	NULL
it	NULL
may	NULL
also	NULL
induce	NULL
apoptosis	NULL
in	NULL
maturing	NULL
APL	NULL
cells	NULL
ATRA	NULL
may	NULL
also	NULL
be	NULL
a	NULL
necessary	NULL
activator	NULL
or	NULL
cofactor	NULL
in	NULL
the	NULL
differentiation	NULL
process	NULL
of	NULL
many	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
behind	NULL
retinoic	NULL
acid-induced	NULL
differentiation	NULL
and	NULL
inhibition	NULL
of	NULL
cell	NULL
growth	NULL
have	NULL
been	NULL
largely	NULL
unknown	NULL
.	NULL

In	NULL
the	NULL
present	NULL
report	NULL
,	NULL
we	NULL
provide	NULL
evidence	NULL
that	NULL
the	NULL
IRF-1	NULL
gene	NULL
,	NULL
a	NULL
potential	NULL
candidate	NULL
gene	NULL
for	NULL
antioncogenic	NULL
functions	NULL
,	NULL
is	NULL
upregulated	NULL
during	NULL
ATRA	NULL
induction	NULL
of	NULL
leukemic	NULL
cells	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
seen	NULL
whether	NULL
similar	NULL
mechanisms	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
other	NULL
forms	NULL
of	NULL
cancer	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
thank	NULL
Dr	NULL
M.	NULL
Lanotte	NULL
(	NULL
INSERM	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
for	NULL
the	NULL
promyelocytic	NULL
NB4	NULL
cell	NULL
line	NULL
.	NULL

We	NULL
thank	NULL
Mari	NULL
Tapaninen	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

122	NULL
REFERENCES	NULL
1	NULL
.	NULL

Chambon	NULL
P	NULL
:	NULL
The	NULL
molecular	NULL
and	NULL
genetic	NULL
dissection	NULL
of	NULL
the	NULL
retinoid	NULL
signaling	NULL
pathway	NULL
.	NULL

Gene	NULL
135:223	NULL
,	NULL
1993	NULL
2	NULL
.	NULL

Grignani	NULL
F	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Longo	NULL
L	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Donti	NULL
E	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
From	NULL
genetics	NULL
to	NULL
treatment	NULL
.	NULL

Blood	NULL
83:10	NULL
,	NULL
1994	NULL
3	NULL
.	NULL

Warrel	NULL
RP	NULL
,	NULL
Maslak	NULL
P	NULL
,	NULL
Eardley	NULL
A	NULL
,	NULL
Heller	NULL
G	NULL
,	NULL
Miller	NULL
WH	NULL
,	NULL
Frankel	NULL
SR	NULL
:	NULL
Treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
:	NULL
An	NULL
update	NULL
of	NULL
the	NULL
New	NULL
York	NULL
experience	NULL
.	NULL

Leukemia	NULL
8:929	NULL
,	NULL
1994	NULL
4	NULL
.	NULL

Degos	NULL
L	NULL
,	NULL
Dombret	NULL
H	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Daniel	NULL
M-T	NULL
,	NULL
Miclea	NULL
J-M	NULL
,	NULL
Chastang	NULL
C	NULL
,	NULL
Castaigne	NULL
S	NULL
,	NULL
Fenaux	NULL
P	NULL
:	NULL
All-trans-retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiating	NULL
agent	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
Â§5:2643	NULL
,	NULL
1995	NULL
5	NULL
.	NULL

Grignani	NULL
F	NULL
,	NULL
Ferrucci	NULL
PF	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Talamo	NULL
G	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Peschle	NULL
C	NULL
,	NULL
Nicoletti	NULL
I	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
The	NULL
acute	NULL
promyelocytic-specific	NULL
PML-RARa	NULL
fusion	NULL
protein	NULL
inhibits	NULL
differentiation	NULL
and	NULL
promotes	NULL
survival	NULL
of	NULL
myeloid	NULL
precursor	NULL
cells	NULL
.	NULL

Cell	NULL
74:423	NULL
,	NULL
1993	NULL
6	NULL
.	NULL

Rousselot	NULL
P	NULL
,	NULL
Hardas	NULL
B	NULL
,	NULL
Patel	NULL
A	NULL
,	NULL
Guidez	NULL
F	NULL
,	NULL
Giken	NULL
J	NULL
,	NULL
Castaigne	NULL
S	NULL
,	NULL
Dejean	NULL
A	NULL
,	NULL
de	NULL
The	NULL
H	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Farzaneh	NULL
F	NULL
,	NULL
Chomienne	NULL
C	NULL
:	NULL
The	NULL
PML-RARa	NULL
gene	NULL
product	NULL
of	NULL
the	NULL
t	NULL
(	NULL
15,17	NULL
)	NULL
translocation	NULL
inhibits	NULL
retinoic	NULL
acid-induced	NULL
granulocytic	NULL
differentiation	NULL
and	NULL
mediated	NULL
trans-activation	NULL
in	NULL
human	NULL
myeloid	NULL
cells	NULL
.	NULL

Oncogene	NULL
9:545	NULL
,	NULL
1994	NULL
7	NULL
.	NULL

Lanotte	NULL
M	NULL
,	NULL
Martin-Thouvenin	NULL
V	NULL
,	NULL
Najman	NULL
S	NULL
,	NULL
Balerini	NULL
P	NULL
,	NULL
Va-lensi	NULL
F	NULL
,	NULL
Berger	NULL
R	NULL
:	NULL
NB4	NULL
,	NULL
a	NULL
maturation	NULL
inducible	NULL
cell	NULL
line	NULL
with	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
marker	NULL
isolated	NULL
from	NULL
a	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
M3	NULL
)	NULL
.	NULL

Blood	NULL
77:1080	NULL
,	NULL
1991	NULL
8	NULL
.	NULL

Huang	NULL
M	NULL
,	NULL
Ye	NULL
YC	NULL
,	NULL
Chen	NULL
BR	NULL
,	NULL
Chai	NULL
JR	NULL
,	NULL
Lu	NULL
JX	NULL
,	NULL
Zhoa	NULL
L	NULL
,	NULL
Gu	NULL
LJ	NULL
,	NULL
Wang	NULL
ZY	NULL
:	NULL
Use	NULL
of	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
72:567	NULL
,	NULL
1988	NULL
9	NULL
.	NULL

Castaigne	NULL
S	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Ballerini	NULL
P	NULL
,	NULL
Berger	NULL
R	NULL
,	NULL
Fenaux	NULL
P	NULL
,	NULL
Degos	NULL
L	NULL
:	NULL
All-trans	NULL
retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

I	NULL
.	NULL

Clinical	NULL
results	NULL
.	NULL

Blood	NULL
76:1704	NULL
,	NULL
1990	NULL
10	NULL
.	NULL

Warrel	NULL
RP	NULL
,	NULL
Frankel	NULL
SR	NULL
,	NULL
Miller	NULL
WH	NULL
,	NULL
Scheinberg	NULL
DA	NULL
,	NULL
Itri	NULL
LM	NULL
,	NULL
HitteIman	NULL
WN	NULL
,	NULL
Vyas	NULL
R	NULL
,	NULL
Andreeff	NULL
M	NULL
,	NULL
Tafuri	NULL
A	NULL
,	NULL
Jakubowski	NULL
A	NULL
,	NULL
Ga-brilove	NULL
J	NULL
,	NULL
Gordon	NULL
MS	NULL
:	NULL
Differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
tretinoin	NULL
(	NULL
all-trans-retinoic	NULL
acid	NULL
)	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
324:1385	NULL
,	NULL
1991	NULL
11	NULL
.	NULL

Sen	NULL
GC	NULL
,	NULL
Ransohoff	NULL
RM	NULL
:	NULL
Interferon-induced	NULL
antiviral	NULL
actions	NULL
and	NULL
their	NULL
regulation	NULL
.	NULL

Adv	NULL
Virus	NULL
Res	NULL
42:57	NULL
,	NULL
1993	NULL
12	NULL
.	NULL

Borden	NULL
EC	NULL
:	NULL
Interferons-expanding	NULL
therapeutic	NULL
roles	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
326:1491	NULL
,	NULL
1992	NULL
13	NULL
.	NULL

Eisenhauer	NULL
EA	NULL
,	NULL
Lippman	NULL
SM	NULL
,	NULL
Cavanagh	NULL
JJ	NULL
,	NULL
Parades-Espinoza	NULL
M	NULL
,	NULL
Amold	NULL
A	NULL
,	NULL
Hong	NULL
WK	NULL
,	NULL
Massimini	NULL
G	NULL
,	NULL
Schleuniger	NULL
U	NULL
,	NULL
Bollag	NULL
W	NULL
,	NULL
Holdener	NULL
EE	NULL
,	NULL
Krakoff	NULL
I	NULL
:	NULL
Combination	NULL
13-cis-retinoic	NULL
acid	NULL
and	NULL
interferon	NULL
Â«	NULL
-2a	NULL
in	NULL
therapy	NULL
of	NULL
solid	NULL
tumors	NULL
.	NULL

Leukemia	NULL
8:1622	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Rysiecki	NULL
G	NULL
,	NULL
Gewert	NULL
DR	NULL
,	NULL
Williams	NULL
BRG	NULL
:	NULL
Constitutive	NULL
expression	NULL
of	NULL
a	NULL
2',5'-oligoadenylate	NULL
synthetase	NULL
cDNA	NULL
results	NULL
in	NULL
increased	NULL
antiviral	NULL
activity	NULL
and	NULL
growth	NULL
suppression	NULL
.	NULL

J	NULL
Interferon	NULL
Res	NULL
9:649	NULL
,	NULL
1989	NULL
15	NULL
.	NULL

Meurs	NULL
EF	NULL
,	NULL
Galabru	NULL
J	NULL
,	NULL
Barber	NULL
GN	NULL
,	NULL
Katze	NULL
MG	NULL
,	NULL
Hovanessian	NULL
AG	NULL
:	NULL
Tumor	NULL
suppressor	NULL
function	NULL
of	NULL
the	NULL
interferon-induced	NULL
double-stranded	NULL
RNA-activated	NULL
protein	NULL
kinase	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:2232	NULL
,	NULL
1993	NULL
16	NULL
.	NULL

Hassel	NULL
BA	NULL
,	NULL
Zhou	NULL
A	NULL
,	NULL
Sotomayor	NULL
CA	NULL
:	NULL
Dominant	NULL
negative	NULL
mutant	NULL
of	NULL
2-5A-dependent	NULL
RNase	NULL
suppresses	NULL
antiproliferative	NULL
and	NULL
antiviral	NULL
effects	NULL
of	NULL
interferon	NULL
.	NULL

EMBO	NULL
J	NULL
12:3297	NULL
,	NULL
1993	NULL
17	NULL
,	NULL
Lamphier	NULL
M	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
The	NULL
transcription	NULL
factors	NULL
IRF-1	NULL
and	NULL
IRF2	NULL
:	NULL
Linking	NULL
the	NULL
interferon	NULL
response	NULL
and	NULL
cell	NULL
growth	NULL
control	NULL
.	NULL

Immunologist	NULL
2:167	NULL
,	NULL
1994	NULL
18	NULL
.	NULL

Veals	NULL
SA	NULL
,	NULL
Schindler	NULL
C	NULL
,	NULL
Leonard	NULL
D	NULL
,	NULL
Fu	NULL
X-Y	NULL
,	NULL
Aebersold	NULL
R	NULL
,	NULL
Darnell	NULL
J	NULL
,	NULL
Levy	NULL
DE	NULL
:	NULL
Subunit	NULL
of	NULL
an	NULL
alpha-interferon-responsive	NULL
tran	NULL
MATIKAINEN	NULL
ET	NULL
AL	NULL
scription	NULL
factor	NULL
is	NULL
related	NULL
to	NULL
interferon	NULL
regulatory	NULL
factor	NULL
and	NULL
myb	NULL
families	NULL
of	NULL
DNA-binding	NULL
protein	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
12:3315	NULL
,	NULL
1992	NULL
19	NULL
.	NULL

Willman	NULL
CL	NULL
,	NULL
Sever	NULL
CE	NULL
,	NULL
Pallavicini	NULL
MG	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
Tnaka	NULL
N	NULL
,	NULL
Slovak	NULL
ML	NULL
,	NULL
Yamamoto	NULL
H	NULL
,	NULL
Harada	NULL
K	NULL
,	NULL
Meeker	NULL
TC	NULL
,	NULL
List	NULL
AF	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
Deletion	NULL
of	NULL
IRF-1	NULL
,	NULL
mapping	NULL
to	NULL
chromosome	NULL
5q31.1	NULL
,	NULL
in	NULL
human	NULL
leukemia	NULL
and	NULL
preleukemic	NULL
myelodysplasia	NULL
.	NULL

Science	NULL
259:968	NULL
,	NULL
1993	NULL
20	NULL
.	NULL

Boultwood	NULL
J	NULL
,	NULL
Lewis	NULL
S	NULL
,	NULL
Wainscoat	NULL
JS	NULL
:	NULL
The	NULL
5q-	NULL
syndrome	NULL
.	NULL

Blood	NULL
84:3253	NULL
,	NULL
1994	NULL
21	NULL
.	NULL

Cantell	NULL
K	NULL
,	NULL
Hirvonen	NULL
S	NULL
,	NULL
Kauppinen	NULL
H-L	NULL
,	NULL
Myllyl	NULL
&	NULL
G	NULL
:	NULL
Production	NULL
of	NULL
interferon	NULL
in	NULL
human	NULL
leukocytes	NULL
from	NULL
normal	NULL
donors	NULL
with	NULL
the	NULL
use	NULL
of	NULL
Sendai	NULL
virus	NULL
,	NULL
Methods	NULL
Enzymol	NULL
78:29	NULL
,	NULL
1981	NULL
22	NULL
.	NULL

Cantell	NULL
K	NULL
,	NULL
Hirvonen	NULL
S	NULL
,	NULL
Kauppinen	NULL
H-L	NULL
:	NULL
Production	NULL
and	NULL
partial	NULL
purification	NULL
of	NULL
human	NULL
immune	NULL
interferon	NULL
.	NULL

Methods	NULL
Enzymol	NULL
119:54	NULL
,	NULL
1986	NULL
23	NULL
.	NULL

Chirgwin	NULL
JM	NULL
,	NULL
Przybyla	NULL
AE	NULL
,	NULL
MacDonald	NULL
RJ	NULL
,	NULL
Rutter	NULL
WJ	NULL
:	NULL
Isolation	NULL
of	NULL
biologically	NULL
active	NULL
ribonucleic	NULL
acid	NULL
from	NULL
sources	NULL
enriched	NULL
in	NULL
ribonuclease	NULL
.	NULL

Biochemistry	NULL
18:5294	NULL
,	NULL
1979	NULL
24	NULL
.	NULL

Glisin	NULL
V	NULL
,	NULL
Crkvenjankov	NULL
R	NULL
,	NULL
Byus	NULL
C	NULL
:	NULL
Ribonucleic	NULL
acid	NULL
isolated	NULL
by	NULL
cesium	NULL
chloride	NULL
centrifugation	NULL
.	NULL

Biochemistry	NULL
13:2633	NULL
,	NULL
1974	NULL
25	NULL
.	NULL

Schwab	NULL
M	NULL
,	NULL
Alitalo	NULL
K	NULL
,	NULL
Varmus	NULL
HE	NULL
,	NULL
Bishop	NULL
JM	NULL
,	NULL
George	NULL
DA	NULL
:	NULL
A	NULL
cellular	NULL
oncogene	NULL
(	NULL
c-Ki-ras	NULL
)	NULL
is	NULL
amplified	NULL
,	NULL
overexpressed	NULL
,	NULL
and	NULL
located	NULL
within	NULL
karyotypic	NULL
abnormalities	NULL
in	NULL
mouse	NULL
adrenocortical	NULL
tumor	NULL
cells	NULL
.	NULL

Nature	NULL
303:497	NULL
,	NULL
1983	NULL
26	NULL
.	NULL

Maruyama	NULL
M	NULL
,	NULL
Fujita	NULL
T	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
Sequence	NULL
of	NULL
a	NULL
cDNA	NULL
coding	NULL
for	NULL
IRF-1	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
17:3292	NULL
,	NULL
1989	NULL
27	NULL
.	NULL

Benech	NULL
P	NULL
,	NULL
Mory	NULL
Y	NULL
,	NULL
Chebath	NULL
J	NULL
:	NULL
Structure	NULL
of	NULL
two	NULL
forms	NULL
of	NULL
the	NULL
interferon-induced	NULL
(	NULL
2'-5	NULL
'	NULL
)	NULL
oligo	NULL
A	NULL
synthetase	NULL
of	NULL
human	NULL
cells	NULL
based	NULL
on	NULL
cDNAs	NULL
and	NULL
gene	NULL
sequences	NULL
.	NULL

EMBO	NULL
J	NULL
4:2249	NULL
,	NULL
1985	NULL
28	NULL
.	NULL

Ronni	NULL
T	NULL
,	NULL
Sareneva	NULL
T	NULL
,	NULL
Pirhonen	NULL
J	NULL
,	NULL
Julkunen	NULL
I	NULL
:	NULL
Activation	NULL
of	NULL
IFN-	NULL
,	NULL
IFN-y	NULL
,	NULL
MxA	NULL
and	NULL
IFN	NULL
regulatory	NULL
factor	NULL
1	NULL
genes	NULL
in	NULL
influenza	NULL
A	NULL
virus-infected	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

J	NULL
Im-munol	NULL
154	NULL
;	NULL
:2764	NULL
,	NULL
1995	NULL
29	NULL
.	NULL

Greenberg	NULL
ME	NULL
,	NULL
Ziff	NULL
EB	NULL
:	NULL
Stimulation	NULL
of	NULL
3T3	NULL
cells	NULL
induces	NULL
transcription	NULL
of	NULL
c-fos	NULL
proto-oncogene	NULL
.	NULL

Nature	NULL
311:433	NULL
,	NULL
1984	NULL
30	NULL
.	NULL

Matikainen	NULL
S	NULL
,	NULL
Tapiovaara	NULL
H	NULL
,	NULL
Vaheri	NULL
A	NULL
,	NULL
Hurme	NULL
M	NULL
:	NULL
Activation	NULL
of	NULL
interleukin-1	NULL
#	NULL
gene	NULL
expression	NULL
during	NULL
retinoic	NULL
acid-induced	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
promyeloid	NULL
leukemia	NULL
cells	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
5:975	NULL
,	NULL
1994	NULL
31	NULL
.	NULL

Andrews	NULL
NC	NULL
,	NULL
Faller	NULL
DV	NULL
:	NULL
A	NULL
rapid	NULL
micropreparation	NULL
technique	NULL
for	NULL
extraction	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
from	NULL
limited	NULL
numbers	NULL
of	NULL
mammalian	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
19:2499	NULL
,	NULL
1991	NULL
32	NULL
.	NULL

Laemmli	NULL
UK	NULL
:	NULL
Cleavage	NULL
of	NULL
structural	NULL
proteins	NULL
during	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
head	NULL
of	NULL
bacteriophage	NULL
T4	NULL
.	NULL

Nature	NULL
227:680	NULL
,	NULL
1970	NULL
33	NULL
.	NULL

Collins	NULL
SJ	NULL
:	NULL
The	NULL
HL-60	NULL
promyelocytic	NULL
leukaemia	NULL
cell	NULL
line	NULL
:	NULL
Proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
cellular	NULL
oncogene	NULL
expression	NULL
.	NULL

Blood	NULL
70:1233	NULL
,	NULL
1987	NULL
34	NULL
.	NULL

Dalton	NULL
WT	NULL
,	NULL
Ahearn	NULL
MJ	NULL
,	NULL
McCredle	NULL
KB	NULL
,	NULL
Freireich	NULL
EJ	NULL
,	NULL
Stass	NULL
SA	NULL
,	NULL
Trujillo	NULL
JM	NULL
:	NULL
HL-60	NULL
cell	NULL
line	NULL
was	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
FAB-M2	NULL
and	NULL
not	NULL
FAB-M3	NULL
.	NULL

Blood	NULL
71:242	NULL
,	NULL
1988	NULL
35	NULL
.	NULL

Auwerx	NULL
J	NULL
;	NULL
The	NULL
human	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
THP-1	NULL
:	NULL
A	NULL
multifaceted	NULL
model	NULL
for	NULL
the	NULL
study	NULL
of	NULL
monocyte-macrophage	NULL
differentiation	NULL
.	NULL

Experientia	NULL
47:22	NULL
,	NULL
1991	NULL
36	NULL
.	NULL

Matikainen	NULL
S	NULL
,	NULL
Hurme	NULL
M	NULL
:	NULL
Comparison	NULL
of	NULL
retinoic	NULL
acid	NULL
and	NULL
phorbol	NULL
ester	NULL
as	NULL
inducers	NULL
of	NULL
monocytic	NULL
differentiation	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
57:98	NULL
,	NULL
1994	NULL
37	NULL
.	NULL

Olsson	NULL
IL	NULL
,	NULL
Breitman	NULL
TR	NULL
:	NULL
Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
histiocytic	NULL
lymphoma	NULL
cell	NULL
line	NULL
U-937	NULL
by	NULL
retinoic	NULL
acid	NULL
and	NULL
cyclic	NULL
agents	NULL
.	NULL

Cancer	NULL
Res	NULL
42:3924	NULL
,	NULL
1982	NULL
38	NULL
.	NULL

Pine	NULL
R	NULL
,	NULL
Canova	NULL
A	NULL
,	NULL
Schindler	NULL
C	NULL
:	NULL
Tyrosine	NULL
phosphorylated	NULL
p91	NULL
binds	NULL
to	NULL
a	NULL
single	NULL
element	NULL
in	NULL
the	NULL
ISGF2/IRF-1	NULL
promoter	NULL
to	NULL
mediate	NULL
induction	NULL
by	NULL
IFNa	NULL
and	NULL
IFNy	NULL
,	NULL
and	NULL
is	NULL
likely	NULL
to	NULL
autoregulate	NULL
the	NULL
p91	NULL
gene	NULL
.	NULL

EMBO	NULL
J	NULL
13:158	NULL
,	NULL
1994	NULL
39	NULL
.	NULL

Ihle	NULL
JN	NULL
:	NULL
Cytokine	NULL
receptor	NULL
signaling	NULL
.	NULL

Nature	NULL
377:591	NULL
,	NULL
1995	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

RETINOIC	NULL
ACID	NULL
ACTIVATES	NULL
IRF-1	NULL
GENE	NULL
EXPRESSION	NULL
40	NULL
.	NULL

Raz	NULL
R	NULL
,	NULL
Durbin	NULL
JE	NULL
,	NULL
Levy	NULL
DE	NULL
:	NULL
Acute	NULL
phase	NULL
response	NULL
factor	NULL
and	NULL
additional	NULL
members	NULL
of	NULL
the	NULL
interferon-stimulated	NULL
gene	NULL
factor	NULL
3	NULL
family	NULL
integrate	NULL
diverse	NULL
signals	NULL
from	NULL
cytokines	NULL
,	NULL
interferons	NULL
,	NULL
and	NULL
growth	NULL
factors	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:24391	NULL
,	NULL
1994	NULL
41	NULL
.	NULL

Fujita	NULL
T	NULL
,	NULL
Reis	NULL
LFL	NULL
,	NULL
Watanabe	NULL
N	NULL
,	NULL
Kimura	NULL
Y	NULL
,	NULL
Taniguchi	NULL
T	NULL
,	NULL
Vilcek	NULL
J	NULL
;	NULL
Induction	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
IRF-1	NULL
and	NULL
mRNAs	NULL
by	NULL
cytokines	NULL
and	NULL
activators	NULL
of	NULL
second-messenger	NULL
pathways	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86:9936	NULL
,	NULL
1989	NULL
42	NULL
.	NULL

Harada	NULL
H	NULL
,	NULL
Takahashi	NULL
E-I	NULL
,	NULL
Itoh	NULL
S	NULL
,	NULL
Harada	NULL
K	NULL
,	NULL
Hori	NULL
T-A	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
Structure	NULL
and	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
(	NULL
IRF-1	NULL
)	NULL
and	NULL
IRF-2	NULL
genes	NULL
:	NULL
Implications	NULL
for	NULL
a	NULL
gene	NULL
network	NULL
in	NULL
the	NULL
interferon	NULL
system	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:1500	NULL
,	NULL
1994	NULL
43	NULL
.	NULL

Harada	NULL
H	NULL
,	NULL
Kitakawa	NULL
M	NULL
,	NULL
Tanaka	NULL
N	NULL
,	NULL
Yamamoto	NULL
H	NULL
,	NULL
Harada	NULL
K	NULL
,	NULL
Ishihara	NULL
M	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
Anti-oncogenic	NULL
and	NULL
oncogenic	NULL
potentials	NULL
of	NULL
interferon	NULL
regulatory	NULL
factors-1	NULL
and	NULL
-2	NULL
.	NULL

Science	NULL
259:971	NULL
,	NULL
1993	NULL
44	NULL
.	NULL

Tanaka	NULL
N	NULL
,	NULL
Ishihara	NULL
M	NULL
,	NULL
Kitagawa	NULL
M	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
Kimura	NULL
T	NULL
,	NULL
Matsuyama	NULL
T	NULL
,	NULL
Lamphier	NULL
MS	NULL
,	NULL
Aizawa	NULL
S	NULL
,	NULL
Mak	NULL
TW	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
Cellular	NULL
commitment	NULL
to	NULL
oncogene-induced	NULL
transformation	NULL
or	NULL
apoptosis	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
transcription	NULL
factor	NULL
IRF-1	NULL
.	NULL

Cell	NULL
77:829	NULL
,	NULL
1994	NULL
45	NULL
.	NULL

Tamura	NULL
T	NULL
,	NULL
Ishihara	NULL
M	NULL
,	NULL
Lamphier	NULL
MS	NULL
,	NULL
Tanaka	NULL
N	NULL
,	NULL
Oishi	NULL
I	NULL
,	NULL
Aizawa	NULL
S	NULL
,	NULL
Matsuyama	NULL
T	NULL
,	NULL
Taki	NULL
S	NULL
,	NULL
Mak	NULL
TW	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
An	NULL
IRF-1	NULL
dependent	NULL
pathway	NULL
of	NULL
DNA	NULL
damage-induced	NULL
apoptosis	NULL
in	NULL
mitogen-activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Nature	NULL
376:596	NULL
,	NULL
1995	NULL
46	NULL
.	NULL

Watanabe	NULL
N	NULL
,	NULL
Sakakibara	NULL
J	NULL
,	NULL
Hovanessian	NULL
AG	NULL
,	NULL
Taniguchi	NULL
T	NULL
,	NULL
Fujita	NULL
T	NULL
:	NULL
Activation	NULL
of	NULL
IFN-beta	NULL
element	NULL
by	NULL
IRF-1	NULL
requires	NULL
a	NULL
post-translational	NULL
event	NULL
in	NULL
addition	NULL
to	NULL
IRF-1	NULL
synthesis	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
19:4421	NULL
,	NULL
1991	NULL
47	NULL
.	NULL

Sims	NULL
SH	NULL
,	NULL
Cha	NULL
Y	NULL
,	NULL
Romine	NULL
MF	NULL
,	NULL
Gao	NULL
P-Q	NULL
,	NULL
Gottlieb	NULL
K	NULL
,	NULL
Deisseroth	NULL
AB	NULL
:	NULL
A	NULL
novel	NULL
interferon-inducible	NULL
domain	NULL
:	NULL
Structural	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
the	NULL
human	NULL
interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
gene	NULL
promoter	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:690	NULL
,	NULL
1993	NULL
48	NULL
.	NULL

Sadowski	NULL
HB	NULL
,	NULL
Shuai	NULL
K	NULL
,	NULL
Darnell	NULL
JE	NULL
,	NULL
Gilman	NULL
MZ	NULL
:	NULL
A	NULL
common	NULL
nuclear	NULL
signal	NULL
transduction	NULL
pathway	NULL
activated	NULL
by	NULL
growth	NULL
factor	NULL
and	NULL
cytokine	NULL
receptors	NULL
.	NULL

Science	NULL
261:1739	NULL
,	NULL
1993	NULL
123	NULL
49	NULL
.	NULL

Zhong	NULL
Z	NULL
,	NULL
Wen	NULL
Z	NULL
,	NULL
Darnell	NULL
JE	NULL
:	NULL
Stat3	NULL
:	NULL
A	NULL
STAT	NULL
family	NULL
member	NULL
activated	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
response	NULL
to	NULL
epidermal	NULL
growth	NULL
factor	NULL
and	NULL
interleukin-6	NULL
.	NULL

Science	NULL
264:95	NULL
,	NULL
1994	NULL
50	NULL
.	NULL

Harroch	NULL
S	NULL
,	NULL
Revel	NULL
M	NULL
,	NULL
Chebath	NULL
J	NULL
:	NULL
Induction	NULL
by	NULL
interleukin-6	NULL
of	NULL
interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
(	NULL
IRF-1	NULL
)	NULL
gene	NULL
expression	NULL
through	NULL
the	NULL
palindromic	NULL
interferon	NULL
response	NULL
element	NULL
pIRE	NULL
and	NULL
cell	NULL
type-dependent	NULL
control	NULL
of	NULL
IRF-1	NULL
binding	NULL
to	NULL
DNA	NULL
.	NULL

EMBO	NULL
J	NULL
13:1942	NULL
,	NULL
1994	NULL
51	NULL
.	NULL

Harada	NULL
H	NULL
,	NULL
Fujita	NULL
T	NULL
,	NULL
Miyamoto	NULL
M	NULL
,	NULL
Kimura	NULL
Y	NULL
,	NULL
Maruyama	NULL
M	NULL
,	NULL
Furia	NULL
A	NULL
,	NULL
Miyata	NULL
T	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
Structurally	NULL
similar	NULL
but	NULL
functionally	NULL
distinct	NULL
factors	NULL
,	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
,	NULL
bind	NULL
to	NULL
the	NULL
same	NULL
regulatory	NULL
elements	NULL
of	NULL
IFN	NULL
and	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

Cell	NULL
58:729	NULL
,	NULL
1989	NULL
52	NULL
.	NULL

Pine	NULL
R	NULL
,	NULL
Decker	NULL
T	NULL
,	NULL
Kessler	NULL
DS	NULL
,	NULL
Levy	NULL
DE	NULL
,	NULL
Darnell	NULL
J	NULL
:	NULL
Purification	NULL
and	NULL
cloning	NULL
of	NULL
interferon-stimulated	NULL
gene	NULL
factor	NULL
2	NULL
(	NULL
ISGF2	NULL
)	NULL
:	NULL
ISGF2	NULL
(	NULL
IRF-1	NULL
)	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
promoters	NULL
of	NULL
both	NULL
beta	NULL
interferon-and	NULL
interferon-stimulated	NULL
genes	NULL
but	NULL
is	NULL
not	NULL
a	NULL
primary	NULL
transcriptional	NULL
activator	NULL
of	NULL
either	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
10:2448	NULL
,	NULL
1990	NULL
53	NULL
.	NULL

Pine	NULL
R	NULL
:	NULL
Constitutive	NULL
expression	NULL
of	NULL
an	NULL
ISGF2/IRF-1	NULL
transgene	NULL
leads	NULL
to	NULL
interferon-independent	NULL
activation	NULL
of	NULL
interferon-inducible	NULL
genes	NULL
and	NULL
resistance	NULL
to	NULL
virus	NULL
infection	NULL
.	NULL

J	NULL
Virol	NULL
66:4470	NULL
,	NULL
1992	NULL
54	NULL
.	NULL

Kimura	NULL
T	NULL
,	NULL
Nakayama	NULL
K	NULL
,	NULL
Penninger	NULL
J	NULL
,	NULL
Kitakawa	NULL
M	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
Matsuyama	NULL
T	NULL
,	NULL
Tanaka	NULL
N	NULL
,	NULL
Kamijo	NULL
R	NULL
,	NULL
Vilcek	NULL
J	NULL
,	NULL
Mak	NULL
TW	NULL
,	NULL
Taniguchi	NULL
T	NULL
:	NULL
Involvement	NULL
of	NULL
the	NULL
IRF-1	NULL
transcription	NULL
factor	NULL
in	NULL
antiviral	NULL
responses	NULL
to	NULL
interferons	NULL
.	NULL

Science	NULL
264:1921	NULL
,	NULL
1994	NULL
55	NULL
.	NULL

Kamijo	NULL
R	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
Matsuyama	NULL
T	NULL
,	NULL
Bosland	NULL
M	NULL
,	NULL
Gerecitano	NULL
J	NULL
,	NULL
Shapiro	NULL
D	NULL
,	NULL
Le	NULL
J	NULL
,	NULL
Koh	NULL
SI	NULL
,	NULL
Kimura	NULL
T	NULL
,	NULL
Green	NULL
SJ	NULL
,	NULL
Mak	NULL
TW	NULL
,	NULL
Taniguchi	NULL
T	NULL
,	NULL
Vilcek	NULL
J	NULL
:	NULL
Requirement	NULL
for	NULL
transcription	NULL
factor	NULL
IRF-1	NULL
in	NULL
NO	NULL
syn-thase	NULL
induction	NULL
in	NULL
macrophages	NULL
.	NULL

Science	NULL
263:1612	NULL
,	NULL
1994	NULL
56	NULL
.	NULL

Briken	NULL
V	NULL
,	NULL
Ruffner	NULL
H	NULL
,	NULL
Schultz	NULL
U	NULL
,	NULL
Schwartz	NULL
A	NULL
,	NULL
Reis	NULL
LFL	NULL
,	NULL
Strehlow	NULL
I	NULL
,	NULL
Decker	NULL
T	NULL
,	NULL
Stacheli	NULL
P	NULL
:	NULL
Interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
is	NULL
required	NULL
for	NULL
mouse	NULL
Gpb	NULL
gene	NULL
activation	NULL
by	NULL
gamma	NULL
interferon	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
15:975	NULL
,	NULL
1995	NULL
57	NULL
.	NULL

Cha	NULL
Y	NULL
,	NULL
Deisseroth	NULL
AB	NULL
:	NULL
Human	NULL
interferon	NULL
regulatory	NULL
factor	NULL
2	NULL
gene	NULL
.	NULL

Intron-exon	NULL
organization	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
5	NULL
``	NULL
-flanking	NULL
region	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:5279	NULL
,	NULL
1994	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

blood	NULL
--	NULL
Retinoic	NULL
acid	NULL
activates	NULL
interferon	NULL
regulatory	NULL
factor-1	NULL
gene	NULL
expression	NULL
in	NULL
myeloid	NULL
cells	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
Â©1004	NULL
@	NULL
207	NULL
S	NULL
Matikainen	NULL
,	NULL
T	NULL
Ronni	NULL
,	NULL
M	NULL
Hurme	NULL
,	NULL
R	NULL
Pine	NULL
and	NULL
|	NULL
Julkunen	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/88/1/114.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

